ContenidosdeElseviersobremedicamentos

    TRANSFORME LA FORMA DE USAR LA INFORMACIÓN SOBRE MEDICAMENTOS

    ¡Conozca más acerca de la información sobre medicamentos de Elsevier hoy mismo! Obtenga los datos sobre medicamentos y el apoyo para la toma de decisiones que necesita, incluidas TRUE Daily Updates™, información actualizada todos los días, incluidos fines de semana y festivos.

    Sep.27.2024

    Chloroquine

    Indications/Dosage

    Labeled

    • amebiasis
    • malaria
    • malaria prophylaxis

    Off-Label

    • discoid lupus erythematosus
    • systemic lupus erythematosus
    † Off-label indication

    For the treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P. knowlesi†, P. malariae, P. ovale, and P. vivax

    Oral dosage

    Adults

    16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily for 2 days.[29758] [68403] For P. vivax or P. ovale, give with primaquine phosphate or tafenoquine.[68403]

    Infants, Children, and Adolescents

    16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily for 2 days.[29758] [66745] [68403] For P. vivax or P. ovale, give in combination with primaquine phosphate or tafenoquine (16 years or older).[68403]

    For malaria prophylaxis

    for primary malaria prophylaxis for travel to areas where chloroquine-resistance has not been reported

    Oral dosage

    Adults

    500 mg (300 mg base) PO once weekly, starting 1 to 2 weeks prior to entry into endemic area and continuing for 4 weeks after leaving the area.[68402] [68404] The FDA-approved dosage is 500 mg (300 mg base) PO once weekly on the same day of each week, starting 2 weeks before entering endemic area and continuing for 8 weeks after leaving the area. If it is not feasible to begin therapy before entering endemic area, use 1,000 mg (600 mg base) as initial loading dose given in 2 divided doses 6 hours apart.[29758]

    Infants, Children, and Adolescents

    8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once weekly, starting 1 to 2 weeks prior to entry into endemic area and continuing for 4 weeks after leaving the area.[66745] [68402] [68404] The FDA-approved dosage is 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once weekly on the same day of each week, starting 2 weeks before entering the endemic area and continuing for 8 weeks after leaving the area. If it is not feasible to begin therapy before entering endemic area, use 16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] as initial loading dose given in 2 divided doses 6 hours apart.[29758]

    for secondary malaria prophylaxis† after acute treatment in pregnant persons with P. vivax or P. ovale infection and able to take primaquine phosphate or tafenoquine after delivery

    Oral dosage

    Adults

    500 mg (300 mg base) PO once weekly for duration of pregnancy. After delivery, subsequent treatment with primaquine phosphate or tafenoquine is needed in persons without G6PD deficiency.[68403]

    Adolescents

    500 mg (300 mg base) PO once weekly for duration of pregnancy. After delivery, subsequent treatment with primaquine phosphate or tafenoquine is needed in persons without G6PD deficiency.[68403]

    for secondary malaria prophylaxis† after acute treatment in pregnant persons with P. vivax or P. ovale infection and G6PD deficiency and unable to tolerate primaquine phosphate or tafenoquine after delivery

    Oral dosage

    Adults

    500 mg (300 mg base) PO once weekly for 1 year after the acute infection.[68403]

    Adolescents

    500 mg (300 mg base) PO once weekly for 1 year after the acute infection.[68403]

    For the treatment of extraintestinal amebiasis (adjunct treatment with an effective intestinal amebicide)

    Oral dosage

    Adults

    1,000 mg (600 mg base) PO once daily for 2 days, then 500 mg (300 mg base) PO once daily for at least 2 to 3 weeks.[29758]

    For the treatment of discoid lupus erythematosus†

    Oral dosage

    Adults

    125 to 250 mg (75 to 150 mg base) PO once daily. Do not exceed 3.5 to 4 mg/kg/day to minimize retinal toxicity. Chloroquine is recommended in patients who fail hydroxychloroquine plus quinacrine; quinacrine may be continued with chloroquine.[62154]

    For the treatment of systemic lupus erythematosus (SLE)†

    Oral dosage

    Adults

    250 mg (150 mg base) PO once daily. Max: 2.3 mg (1.4 mg base)/kg/day.[69023] [69029] Chloroquine may be used if hydroxychloroquine is not available or not tolerated.[69025]

    Therapeutic Drug Monitoring

    Maximum Dosage Limits

    • Adults

      1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO in 48 hours; 500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 mg/day (600 mg base/day) PO for other indications.

    • Geriatric

      1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO in 48 hours; 500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 mg/day (600 mg base/day) PO for other indications.

    • Adolescents

      16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria up to a total of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 8.3 mg/kg/week (5 mg base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO for malaria prophylaxis.

    • Children

      16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria up to a total of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 8.3 mg/kg/week (5 mg base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO for malaria prophylaxis.

    • Infants

      16.6 mg/kg/dose (10 mg base/kg/dose) PO for malaria up to a total of 41.5 mg/kg (25 mg/kg base) PO in 48 hours; 8.3 mg/kg/week (5 mg base/kg/week) PO for malaria prophylaxis.

    • Neonates

      Safety and efficacy have not been established.

    Patients with Hepatic Impairment Dosing

    Chloroquine concentrates in the liver. However, no specific dosage adjustment guidelines are available for patients with hepatic impairment.[29758]

    Patients with Renal Impairment Dosing

    CrCl 10 mL/minute or more: No dosage adjustment necessary.

    CrCl less than 10 mL/minute: Decrease dose by 50%.[32569]

     

    Intermittent hemodialysis:

    Decrease dose by 50%.[32569]

     

    Peritoneal dialysis:

    Decrease dose by 50%.[32569]

     

    Continuous renal replacement therapy:

    No dosage adjustment necessary.[32569]

    † Off-label indication
    Revision Date: 09/27/2024, 03:59:00 AM

    References

    29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.32569 - Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children, 5th ed. Philadelphia: American College of Physicians; 2007.62154 - Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol 2013;27:391-404.66745 - American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.68402 - Tan K, Abanyie F. Chapter 4. Travel-related infectious diseases - malaria. In. Centers for Disease Control and Prevention. 2024 Yellow Book - Traveler's Health. Atlanta: U.S. Department of Health and Human Services, Public Health Service. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria68403 - Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Atlanta, GA: US Department of Health and Human Services; Updated Jun. 2023. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html.68404 - Centers for Disease Control and Prevention. Choosing a drug to prevent malaria. Atlanta, GA: US Department of Health and Human Services; Updated Feb 2023. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://www.cdc.gov/malaria/travelers/drugs.html69023 - Tellez Arevalo AM, Quaye A, Rojas-Rodriguez LC, et al. Synthetic pharmacotherapy for systemic lupus erythematosus: potential mechanisms of action, efficacy, and safety. Medicina (Kaunas). 2022;59:56.69025 - Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:e1-e45.69029 - Meinao I, Sato E, Andrade L, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237-241.

    How Supplied

    Chloroquine Hydrochloride Solution for injection

    Aralen 50mg/ml Solution for Injection (00024-0074) (Sanofi U.S. LLC) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (76385-0142) (Bayshore Pharmaceuticals LLC) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma Pharmaceuticals USA inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma Pharmaceuticals USA Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (00115-2790) (Impax Generics, a division of Impax Laboratories, Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (00115-7056) (Impax Generics, a division of Impax Laboratories, Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (00115-2790) (Impax Generics, a division of Impax Laboratories, Inc.) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising Pharmaceuticals Inc) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising Pharmaceuticals Inc) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 250mg Tablet (63304-0460) (Sun Pharmaceutical Industries, Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Aralen 500mg Tablet (00280-0084) (Bayer Corp Consumer Care Div) (off market)

    Chloroquine Phosphate Oral tablet

    Aralen 500mg Tablet (00024-0084) (Sanofi U.S. LLC) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (23155-0850) (Avet Pharmaceuticals Inc.) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (42291-0047) (AvKARE, Inc.) nullChloroquine Phosphate 500mg Tablet package photo

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (62135-0717) (Chartwell RX LLC) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (00143-2125) (Hikma Pharmaceuticals USA Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (00115-7010) (Impax Generics, a division of Impax Laboratories, Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (00115-7010) (Impax Generics, a division of Impax Laboratories, Inc.) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (55289-0856) (PD-Rx Pharmaceuticals, Inc.) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (43063-0454) (PD-Rx Pharmaceuticals, Inc.) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc) (off market)

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc) null

    Chloroquine Phosphate Oral tablet

    Chloroquine Phosphate 500mg Tablet (63304-0461) (Sun Pharmaceutical Industries, Inc.) (off market)

    Description/Classification

    Description

    Chloroquine is a 4-aminoquinoline anti-protozoal agent indicated for the treatment and prophylaxis of susceptible malaria strains and for the treatment of extraintestinal amebiasis. Chloroquine is not active against gametocytes and the exoerythrocytic forms including the hypnozoite stage of the Plasmodium parasites. Resistance to chloroquine is widespread. Irreversible retinal damage has been observed with use, and postmarketing cases of life-threatening and fatal cardiomyopathy, including ventricular arrhythmias and torsade de pointes (TdP), have been reported.[29758]

    Classifications

    • General Anti-infectives Systemic
      • Antiparasitic Agents, Insecticides, and Repellants
        • Antiprotozoals
          • Agents for Amoebiasis and Other Protozoal Diseases
          • Antimalarials
    Revision Date: 09/27/2024, 03:59:00 AM

    References

    29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.

    Administration Information

    General Administration Information

    For storage information, see the specific product information within the How Supplied section.

    Route-Specific Administration

    Oral Administration

    • May administer with meals in patients who experience gastrointestinal side effects.[68402]

    Oral Solid Formulations

    • To mitigate bitter tablet taste for children, tablets may be pulverized and enclosed in gelatin capsules. If the child is unable to swallow the capsules or tablets, the gelatin capsules may be opened and the contents mixed with a small amount of something sweet, such as applesauce, chocolate syrup, or jelly.[68402]

    Extemporaneous Compounding-Oral

    NOTE: Chloroquine extemporaneous suspension is not FDA-approved.

    Extemporaneous chloroquine suspension has been compounded using the following formulations:

    • Chloroquine phosphate 15 mg/mL in 1:1 Ora-Sweet and Ora-Plus, 1:1 Ora-Sweet SF and Ora-Plus, or Cherry Syrup:
      • Pulverize three 500-mg chloroquine phosphate tablets into a fine powder in a mortar.
      • Add approximately 15 mL of vehicle, which may be a 1:1 mixture of Ora-Sweet and Ora-Plus, 1:1 mixture of Ora-Sweet SF and Ora-Plus, or cherry syrup.
      • Add the vehicle in geometric portions almost to volume and mix thoroughly after each addition.
      • Transfer the contents of the mortar to a calibrated bottle.
      • Add enough vehicle to bring the final volume to 100 mL.
      • Label "Shake Well Before Using" and "Protect from Light"
      • Storage: The suspension is stable for 60 days when stored without light at 5 and 25 degrees C.[62145]
    • Chloroquine base 10 mg/mL in Cherry Syrup:
      • Pulverize two 500-mg chloroquine phosphate tablets in a mortar after removing the film coating.
      • Levigate with a small amount of sterile water.
      • Add by geometric proportions a significant amount of cherry syrup, and levigate until a uniform mixture is obtained.
      • Transfer the contents of the mortar to a conical graduated cylinder.
      • Add enough cherry syrup to bring the final volume to 60 mL.
      • Pour the suspension into an amber glass bottle and shake vigorously.
      • Storage: The suspension is stable for up to 4 weeks under refrigeration (4 degrees C), at room temperature (22 to 25 degrees C), and at 29 degrees C.[62150]
    • Chloroquine base 15 mg/mL in Glycerin or Distilled Water, Cologel (Lilly), and Simple Syrup/Cherry Syrup:
      • Pulverize two 500-mg chloroquine phosphate tablets in a mortar.
      • Levigate with a small amount of glycerin or distilled water.
      • Add 13 mL of Cologel, and levigate until a uniform mixture is obtained.
      • Add by geometric proportion a significant amount of a 2:1 simple syrup/cherry syrup mixture, and levigate until a uniform mixture is obtained.
      • Transfer the contents of the mortar to a conical graduated cylinder.
      • Add enough of the syrup mixture to bring the final volume to 40 mL.
      • Pour the suspension into an amber glass bottle and shake vigorously.
      • Label "Shake Well" and "Refrigerate".
      • Storage: The suspension is stable for 3 days when stored in the refrigerator.[62172]

    Clinical Pharmaceutics Information

    From Trissel's 2‚Ñ¢ Clinical Pharmaceutics Database

    Chloroquine

    pH Range
    pH 5.5 to 6.6 (as the hydrochloride salt)
    ReferencesMcEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American Society of Health-System Pharmacists.
    Stability
    Chloroquine sulfate in intact containers stored as directed by the manufacturer is stable until the labeled expiration date. Infusion Solutions: Chloroquine sulfate 0.5 mg/mL in sodium chloride 0.9% was reported by Martens et al. to be stable for 24 hours at 21 degree C protected from exposure to light.
    ReferencesAnon. Manufacturer's information and labeling. (Package insert).
    ReferencesMartens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47
    Light Exposure
    Chloroquine injection should be protected from exposure to light during long-term storage.
    ReferencesAnon. Manufacturer's information and labeling. (Package insert).
    ReferencesAnon. BIAM; l'Universite et l'Industrie Pharmaceutique, Banque de donnes automatisee surles medicaments (Biam), Paris, France. Accessed at: http://www2.biam2.org.
    ReferencesAnon. South African Electronic Package Inserts, Malahyde Information Systems. Accessed at http://home.intekom.com/pharm/intramed.
    Filtration
    Geary et al. reported that chloroquine exhibited binding to cellulose acetate filters. About 60% or more of the drug was lost from 10 mL of a chloroquine 0.32-mg/mL solution passed through Millipore and Nalgene 0.45-micron cellulose acetate filters. No drug loss occurred when the chloroquine solution was passed through a polycarbonate filter. The clinical implications, if any, of binding to filters from such a low concentration are uncertain.
    ReferencesGeary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J Trop Med Hyg. 1984; 32
    Sorption Leaching
    Geary et al. reported that chloroquine at low concentrations exhibits sorption to glass. As much as 30 to 40% was lost to glass test tubes from a 0.32 mg/mL solution. No loss due to sorption to polycarbonate, polystyrene, or polypropylene plastics was found. The clinical implications, if any, of sorption from such a low concentration are uncertain. Moreover, Martens et al. were unable to confirm this result. They found no sorption to glass bottles, polyvinyl chloride (PVC) plastic bags, and polyethylene-lined laminated bags from a chloroquine 0.5 mg/mL (as sulfate) solution.
    ReferencesD'Arcy PF. Drug interactions with medical plastics. Drug Intell Clin Pharm. 1083; 17
    ReferencesGeary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J Trop Med Hyg. 1984; 32
    ReferencesMartens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47
    Stability Max
    Maximum reported stability period: In NS- 24 hours at room temperature
    ReferencesMartens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47
    Revision Date: 09/27/2024, 03:59:00 AMCopyright 2004-2024 by Lawrence A. Trissel. All Rights Reserved.

    References

    62145 - Allen LV, Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm 1998;55:1915-20.62150 - Mirochnick M, Barnett E, Clarke DF, et al. Stability of chloroquine in an extemporaneously prepared suspension stored at three temperatures. Pediatr Infect Dis J 1994;13:827-8.62172 - ASHP (American Society of Hospital Pharmacists). Committee on extemporaneous formulations. Handbook on Extemporaneous Formulations. Bethesda MD: ASHP, 1987.68402 - Tan K, Abanyie F. Chapter 4. Travel-related infectious diseases - malaria. In. Centers for Disease Control and Prevention. 2024 Yellow Book - Traveler's Health. Atlanta: U.S. Department of Health and Human Services, Public Health Service. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria

    Adverse Reactions

    Severe

    • acute generalized exanthematous pustulosis (AGEP)
    • agranulocytosis
    • anaphylactic shock
    • anaphylactoid reactions
    • angioedema
    • aplastic anemia
    • AV block
    • cardiomyopathy
    • corneal opacification
    • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
    • erythema multiforme
    • exfoliative dermatitis
    • hearing loss
    • hemolytic anemia
    • macular degeneration
    • night blindness
    • pancytopenia
    • retinopathy
    • seizures
    • Stevens-Johnson syndrome
    • suicidal ideation
    • torsade de pointes
    • torticollis
    • toxic epidermal necrolysis
    • ventricular fibrillation
    • ventricular tachycardia
    • visual impairment

    Mild

    • abdominal pain
    • agitation
    • alopecia
    • anorexia
    • anxiety
    • diarrhea
    • hair discoloration
    • headache
    • hyporeflexia
    • insomnia
    • nausea
    • photosensitivity
    • pruritus
    • skin discoloration
    • tinnitus
    • urticaria
    • vomiting
    • weakness

    Moderate

    • blurred vision
    • bundle-branch block
    • confusion
    • corneal deposits
    • delirium
    • depression
    • dyskinesia
    • elevated hepatic enzymes
    • hallucinations
    • hemolysis
    • hepatitis
    • hypoglycemia
    • hypotension
    • myasthenia
    • myopathy
    • neutropenia
    • psoriasis
    • psychosis
    • QT prolongation
    • scotomata
    • thrombocytopenia

    Irreversible maculopathy and macular degeneration have been reported with chloroquine or other 4-aminoquinoline compounds during postmarketing use. Irreversible retinopathy with retinal pigment changes (bull's eye appearance) and visual field defects (paracentral scotomas) have been reported in patients receiving long-term or high-dose 4-aminoquinoline therapy. Visual impairment (i.e., blurred vision and difficulty in focusing or accommodation), nyctalopia (night blindness), scotomatous vision with field defects of paracentral, pericentral ring types, and typically temporal scotomata (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, and fog before the eyes), and reversible corneal opacification (corneal deposits) have been reported. For patients with significant risk factors, monitoring should include annual examinations which include best corrected distance visual acuity (BCVA), automated threshold visual field (VF), and spectral domain optical coherence tomography (SD-OCT). For individuals without significant risk factors, annual exams can usually be deferred until 5 years of treatment. Discontinue chloroquine if ocular toxicity is suspected, and monitor the patient closely as retinal changes and visual disturbances may progress after cessation of therapy.[29758]

    Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pleomorphic skin eruptions, skin and mucosal pigmentary changes (skin discoloration), lichen planus-like eruptions, pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS), photosensitivity, hair loss (alopecia), bleaching of hair pigment (hair discoloration), urticaria, anaphylactoid reactions or anaphylactic shock, and angioedema have been reported during postmarketing use of chloroquine or other 4-aminoquinoline compounds. An acute attack of psoriasis can be precipitated by chloroquine in predisposed patients.[29758]

    Chloroquine has been associated with acute generalized exanthematous pustulosis (AGEP). The non-follicular, pustular, erythematous rash starts suddenly and is associated with fever above 38 degrees C. Drugs are the main cause of AGEP. A period of 2 to 3 weeks after an inciting drug exposure appears necessary for a first episode of AGEP. Unintentional reexposure may cause a second episode within 2 days.[27736]

    Hematological adverse reactions have been reported during postmarketing use of chloroquine or other 4-aminoquinoline compounds and include reversible agranulocytosis, aplastic anemia, pancytopenia, neutropenia, and thrombocytopenia. Chloroquine may cause hemolysis and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency).[29758]

    During postmarketing use, chloroquine and/or other 4-aminoquinoline compounds have been associated with sensorimotor disorders as well as skeletal muscle myopathy or neuromyopathy leading to progressive weakness (myasthenia) and atrophy of proximal muscle groups, depressed tendon reflexes (hyporeflexia), and abnormal nerve conduction. Periodically test knee and ankle reflexes to detect any evidence of muscular weakness. Discontinue chloroquine if weakness develops.[29758]

    Nerve type deafness, tinnitus, and reduced hearing (hearing loss) in patients with preexisting auditory damage have been reported during postmarketing use of chloroquine or other 4-aminoquinoline compounds. Discontinue chloroquine with any hearing defects, and monitor the patient closely.[29758]

    Cardiovascular adverse reactions associated with chloroquine or other 4-aminoquinoline compounds during postmarketing include cardiomyopathy (which may result in cardiac failure and in some cases fatal outcome), electrocardiogram (ECG) changes (particularly, inversion or flattening of the T-wave with widening of the QRS complex), and hypotension. Cardiac arrhythmias, conduction disorders such as bundle-branch block and AV block, QT prolongation, torsade de pointes (TdP), ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation) have been reported, including fatal cases. The risk is greater with higher doses, although cases have been reported with therapeutic doses. Chronic toxicity should be considered when conduction disorders, such as bundle-branch block or AV block, are diagnosed. Additionally, cases of cardiomyopathy resulting in cardiac failure with some cases of fatal outcome have been reported with chloroquine. Prompt discontinuation of chloroquine may prevent life-threatening complications if cardiotoxicity is suspected.[28225] [28229] [28230] [28231] [29758]

    Adverse gastrointestinal effects noted with chloroquine or other 4-aminoquinoline compounds during postmarketing include hepatitis, elevated hepatic enzymes, nausea, vomiting, abdominal pain/cramps, diarrhea, and anorexia.[29758] Gastric effects can be minimized by taking chloroquine with food.[61673]

    Nervous system adverse reactions associated with chloroquine or other 4-aminoquinoline compounds during postmarketing include headache (usually mild and transient), seizures, polyneuropathy, acute extrapyramidal symptoms (e.g., dystonia, dyskinesia, tongue protrusion, torticollis), and neuropsychiatric changes including psychosis, delirium, anxiety, agitation, insomnia, hallucinations, confusion, personality changes, depression, and suicidal ideation/behavior. Extrapyramidal symptoms usually resolve after treatment discontinuation and/or symptomatic treatment.[29758]

    Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications. Monitor blood glucose and adjust treatment as necessary in patients presenting with clinical symptoms of hypoglycemia during chloroquine treatment.[29758]

    Revision Date: 09/27/2024, 03:59:00 AM

    References

    27736 - Beylot C, Doutre M, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 1996;15(4):244-249.28225 - CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web at http://www.crediblemeds.org.28229 - Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.28230 - Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. Postgrad Med J 2001;77:344, 352-3.28231 - Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5.29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.61673 - Anon. Drugs for Parasitic Infections. Med Lett Drugs Ther 2013;11S:e1-31.

    Contraindications/Precautions

    Absolute contraindications are italicized.

    • chloroquine hypersensitivity
    • ocular disease
    • accidental exposure
    • alcoholism
    • apheresis
    • Asian patients
    • AV block
    • bradycardia
    • breast-feeding
    • cardiomyopathy
    • celiac disease
    • children
    • congenital long QT syndrome
    • diabetes mellitus
    • Fabry disease
    • females
    • fever
    • G6PD deficiency
    • geriatric
    • hearing impairment
    • heart failure
    • hepatic disease
    • human immunodeficiency virus (HIV) infection
    • hydroxychloroquine hypersensitivity
    • hyperparathyroidism
    • hypocalcemia
    • hypoglycemia
    • hypokalemia
    • hypomagnesemia
    • hypothermia
    • hypothyroidism
    • infants
    • infertility
    • myocardial infarction
    • neonates
    • neurological disease
    • pheochromocytoma
    • porphyria
    • pregnancy
    • psoriasis
    • QT prolongation
    • renal failure
    • renal impairment
    • rheumatoid arthritis
    • seizure disorder
    • seizures
    • sickle cell disease
    • sleep deprivation
    • stroke
    • systemic lupus erythematosus

    Chloroquine is reported in the literature to be a weak genotoxic agent that may elicit both gene mutations and chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or induction of oxidative stress. Both positive and negative results have been reported with in vitro reverse gene mutation assays and with in vivo animal studies. The chromosomal effects were not observed when chloroquine was administered to animals orally.[29758]

    Use of chloroquine for indications other than acute malaria is contraindicated in patients with ocular disease, specifically those who have retinal or visual field changes of any etiology. Irreversible retinal damage has been observed in some patients who received chloroquine. Significant risk factors for retinal damage include daily doses of chloroquine phosphate more than 2.3 mg/kg of actual body weight, duration of use more than 5 years, subnormal glomerular filtration (renal impairment or renal failure), use of some concomitant drug products such as tamoxifen, and concurrent macular disease. Baseline ophthalmological examination should be performed within the first year of starting chloroquine and should include best corrected distance visual acuity (BCVA), automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain optical coherence tomography (SD-OCT). In Asian patients, retinal toxicity may first be noticed outside the macula, and VF testing should be performed in the central 24 degrees instead of the central 10 degrees. For patients with significant risk factors, monitoring should include annual examinations which include BCVA, VF, and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until 5 years of treatment. Discontinue chloroquine if ocular toxicity is suspected, and monitor the patient closely as retinal changes and visual disturbances may progress after cessation of therapy.[29758] The use of chloroquine should be approached with caution in patients with Fabry disease, particularly those with ocular symptoms. The drug can cause a keratopathy that is clinically and ultrastructurally indistinguishable from keratopathy caused by Fabry disease; this drug-induced keratopathy is reversible with drug cessation. In addition, chloroquine poses a theoretical risk of decreased intracellular alpha-galactosidase A activity in Fabry disease patients. Chloroquine has been reported to induce clinical symptoms that mimic those of Fabry disease, including formation of inclusion bodies that are biochemically and ultrastructurally similar in most of the cells affected by Fabry disease (e.g., striated muscle, smooth muscle, etc.). The distinguishing factor is that the ultrastructural features of chloroquine toxicity in striated muscle, curvilinear bodies, are not present in renal cells.[30609]

    Chloroquine is contraindicated in patients with known chloroquine hypersensitivity, or with a known allergy to 4-aminoquinolines. Patients with hydroxychloroquine hypersensitivity may have cross sensitivity to chloroquine.[29758]

    QT prolongation, torsade de pointes (TdP), and ventricular arrhythmias have been reported with chloroquine use. The risk is greater with higher doses, although cases have been reported with therapeutic doses.[28225] [28229] [28230] [28231] [29758] Use chloroquine with caution in patients with conditions that may increase the risk of QT prolongation including congenital long QT syndrome, bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial infarction, stroke, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, geriatric patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, hypothyroidism, hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus (HIV) infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus (SLE), and celiac disease) and patients undergoing apheresis procedures (e.g., plasmapheresis [plasma exchange], cytapheresis) may also be at increased risk for QT prolongation.[28432] [28457] [29758] [56592] [65180] Consider chronic chloroquine toxicity when conduction disorders, such as bundle-branch block or AV block, are diagnosed. Cases of cardiomyopathy resulting in cardiac failure, sometimes fatal, have been reported with chloroquine. Prompt discontinuation of chloroquine may prevent life-threatening complications if cardiotoxicity is suspected.[29758]

    Chloroquine should not be used in patients with psoriasis unless the benefit to the patient outweighs the potential risks because it may precipitate a severe attack of psoriasis.[29758]

    Chloroquine should be used with caution in patients with hepatic disease or alcoholism because the drug is metabolized in the liver and accumulation can occur producing toxic effects. Patients receiving other hepatotoxic drugs also should be treated with caution.[29758]

    Chloroquine should be used with caution in patients with neurological disease including preexisting hearing impairment or seizure disorder. Polyneuritis, ototoxicity, seizures, neuromyopathy, and acute extrapyramidal symptoms (dystonia, dyskinesia, tongue protrusion, torticollis) have occurred with chloroquine therapy. Symptoms of muscle weakness and response of knee and ankle reflexes should be investigated regularly. If muscle weakness, extrapyramidal symptoms, or any defects in hearing occur during chloroquine therapy, the drug should be discontinued immediately and the patient observed closely.[29758]

    Chloroquine can exacerbate porphyria or may cause hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency). Use chloroquine with caution in patients with these conditions. Blood monitoring for hemolytic anemia in G6PD deficiency patients may be necessary, particularly with concomitant use of other medications associated with hemolysis.[29758]

    Use chloroquine with caution in patients with hypoglycemia or diabetes mellitus. Chloroquine can cause severe, life-threatening hypoglycemia in patients with or without antidiabetic medications. Warn patients about the risk of hypoglycemia and the associated clinical signs and symptoms. Monitor blood glucose and adjust treatment as necessary in patients presenting with clinical symptoms of hypoglycemia during chloroquine treatment.[29758]

    Children are especially sensitive to the 4-aminoquinoline compounds. Fatalities have been reported after accidental exposure of chloroquine; some cases involved relatively small doses (e.g., 0.75 g or 1 g in a 3-year-old child). Strongly warn patients to keep chloroquine out of the reach of pediatric patients, including neonates, infants, children, and adolescents.[29758]

    Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to the fetus, and consider the drug's potential to remain in the body for several months after discontinuation of therapy.[29758] [68402] [68403] In humans at recommended doses for prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a small number of prospective studies with chloroquine during pregnancy, have shown no increase in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend chloroquine as a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters. Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater than the drug's risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects when administered during pregnancy.[68402] [68403] Animal studies showed embryo-fetal developmental toxicity at doses 3 to 16 times the maximum recommended therapeutic dose and the potential of genotoxicity in some test systems. Autoradiographic studies have shown accumulation in the eyes and ears when chloroquine is administered at the start or end of gestation in animal studies.[29758]

    Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted into breast milk. The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in 11 lactating mothers following a single oral dose of chloroquine (600 mg base).The maximum daily dose of the drug that the infant received from breast-feeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for an infant is required.[29758] However, previous American Academy of Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding, and chloroquine has an established dosage in infants.[27500]

    Chloroquine should be used with caution in males because animal studies suggest that infertility is possible; after 30 days of oral treatment, testosterone levels and weight of testes, epididymis, seminal vesicles, and prostate decreased.[29758]

    Revision Date: 09/27/2024, 03:59:00 AM

    References

    27500 - American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.28225 - CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web at http://www.crediblemeds.org.28229 - Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.28230 - Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. Postgrad Med J 2001;77:344, 352-3.28231 - Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5.28432 - Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.28457 - Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.30609 - Albay D, Adler SG, Philipose J, et al. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 2005;18:733-8.56592 - van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.65180 - Woosley RL, Heise CW, Gallo T, et al. QTFactors List. Oro Valley, AZ: AZCERT, Inc.; Accessed March 31, 2020. Available on the World Wide Web at: https://crediblemeds.org/ndfa-list/68402 - Tan K, Abanyie F. Chapter 4. Travel-related infectious diseases - malaria. In. Centers for Disease Control and Prevention. 2024 Yellow Book - Traveler's Health. Atlanta: U.S. Department of Health and Human Services, Public Health Service. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria68403 - Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Atlanta, GA: US Department of Health and Human Services; Updated Jun. 2023. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html.

    Mechanism of Action

    Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism is unknown. Chloroquine may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Chloroquine is not active against gametocytes and the exoerythrocytic forms, including the hypnozoite stage (P. vivax and P. ovale) of the Plasmodium parasites. Organisms with reduced susceptibilities to hydroxychloroquine also show reduced susceptibilities to chloroquine.[29758]

     

    Although the mechanisms underlying the antiinflammatory and immunomodulatory effects of chloroquine are unknown, several possible mechanisms of action have been proposed. It is unclear if these mechanisms work similarly for rheumatic and autoimmune diseases. Potential mechanisms include reduced cytokine production, inhibition of immune effector cells, inhibition of platelet function, protection of the cell surface from external disturbances, competitive binding to nucleic acid ligands or toll-like receptors (TLRs), interference with lysosomal function, reduction of leakage of lysosomal enzymes, and interference with endosomal NADPH oxidase (NOX).[61727] [61728] [61729]

    Revision Date: 09/27/2024, 03:59:00 AM

    References

    29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.61727 - Muller-Calleja N, Manukyan D, Canisius A, et al. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis 2016. Epub ahead of print, doi: 10.1136/annrheumdis-2016-210012.61728 - Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-804.61729 - Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996;S1:S4-10.

    Pharmacokinetics

    Chloroquine is administered orally. It is widely distributed into body tissues, with higher concentrations in the liver, kidneys, spleen, and lungs. Leukocytes also concentrate the drug. Smaller amounts of the drug are found in the brain and spinal cord. Cells containing melanin in the eyes and skin bind strongly to chloroquine. The drug also concentrates in erythrocytes and is bound to platelets and granulocytes. It is about 55% bound to plasma protein.[29758] [61731] [62151]

     

    Excretion of chloroquine is largely through urine, but this is a slow process and may be increased by acidification of the urine. Chloroquine undergoes appreciable degradation in the body, and the major metabolite is desethylchloroquine. Slightly more than half of a dose is excreted in urine as unchanged drug and about 25% as the major metabolite; bisdesethylchloroquine and other metabolic products are found in small amounts. A small portion of the unabsorbed drug is excreted in the feces. Elimination appears to take place in a biphasic manner. The elimination half-life is 108 to 291 hours.[29758] [61731] [62151]

     

    Affected cytochrome P450 isoenzymes and drug transporters: CYP2C8, CYP2D6, CYP3A4, P-gp

    In vitro data suggest that chloroquine is metabolized primarily by CYP2C8 and CYP3A4, and to a much lesser extent, by CYP2D6.[65236] [65239] It has also been shown to be an inhibitor of the drug transporter P-glycoprotein (P-gp).[65237]

    Route-Specific Pharmacokinetics

    Oral Route

    After oral administration, chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract.[29758][62151] The Tmax is 2.7 to 6.9 hours with a Cmax of 283 to 1,430 ng/mL and an AUC of 8.2 to 140 mcg x hour/mL.[62151] A single study showed that the AUC in patients with malaria was higher than in normal volunteers (281 vs. 122 mcg x mL/L x hour).[61760]

    Revision Date: 09/27/2024, 03:59:00 AM

    References

    29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.61731 - Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983;75:5-10.61760 - Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5(S1):S11-15.62151 - Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015. Available on the worldwide web: https://www.ncbi.nlm.nih.gov/books/NBK294440/.65236 - Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Rheumatology 2020;16:155-166.65237 - Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 1996;7:568-578.65239 - Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003;31:748-754.

    Pregnancy/Breast-feeding

    pregnancy

    Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to the fetus, and consider the drug's potential to remain in the body for several months after discontinuation of therapy.[29758] [68402] [68403] In humans at recommended doses for prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a small number of prospective studies with chloroquine during pregnancy, have shown no increase in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend chloroquine as a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters. Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater than the drug's risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects when administered during pregnancy.[68402] [68403] Animal studies showed embryo-fetal developmental toxicity at doses 3 to 16 times the maximum recommended therapeutic dose and the potential of genotoxicity in some test systems. Autoradiographic studies have shown accumulation in the eyes and ears when chloroquine is administered at the start or end of gestation in animal studies.[29758]

    breast-feeding

    Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted into breast milk. The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in 11 lactating mothers following a single oral dose of chloroquine (600 mg base).The maximum daily dose of the drug that the infant received from breast-feeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for an infant is required.[29758] However, previous American Academy of Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding, and chloroquine has an established dosage in infants.[27500]

    Revision Date: 09/27/2024, 03:59:00 AM

    References

    27500 - American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.68402 - Tan K, Abanyie F. Chapter 4. Travel-related infectious diseases - malaria. In. Centers for Disease Control and Prevention. 2024 Yellow Book - Traveler's Health. Atlanta: U.S. Department of Health and Human Services, Public Health Service. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria68403 - Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Atlanta, GA: US Department of Health and Human Services; Updated Jun. 2023. Retrieved Oct. 31, 2023. Available on the World Wide Web at: https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html.

    Interactions

    Level 1 (Severe)

    • Cisapride
    • Dronedarone
    • Ketoconazole
    • Levoketoconazole
    • Pimozide
    • Thioridazine

    Level 2 (Major)

    • Adagrasib
    • Alfuzosin
    • Alogliptin
    • Alogliptin; Metformin
    • Alogliptin; Pioglitazone
    • Aluminum Hydroxide
    • Aluminum Hydroxide; Magnesium Carbonate
    • Aluminum Hydroxide; Magnesium Hydroxide
    • Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
    • Aluminum Hydroxide; Magnesium Trisilicate
    • Amiodarone
    • Amisulpride
    • Amoxicillin; Clarithromycin; Omeprazole
    • Anagrelide
    • Antacids
    • Apomorphine
    • Aripiprazole
    • Arsenic Trioxide
    • Artemether; Lumefantrine
    • Asenapine
    • Aspirin, ASA; Citric Acid; Sodium Bicarbonate
    • Atomoxetine
    • Azithromycin
    • Bedaquiline
    • Bexagliflozin
    • Bismuth Subcitrate Potassium; Metronidazole; Tetracycline
    • Bismuth Subsalicylate; Metronidazole; Tetracycline
    • Buprenorphine
    • Buprenorphine; Naloxone
    • Cabotegravir; Rilpivirine
    • Calcium Carbonate
    • Calcium Carbonate; Famotidine; Magnesium Hydroxide
    • Calcium Carbonate; Magnesium Hydroxide
    • Calcium Carbonate; Magnesium Hydroxide; Simethicone
    • Calcium Carbonate; Simethicone
    • Calcium; Vitamin D
    • Canagliflozin
    • Canagliflozin; Metformin
    • Ceritinib
    • Chlorpromazine
    • Cholera Vaccine
    • Cimetidine
    • Ciprofloxacin
    • Citalopram
    • Clarithromycin
    • Clofazimine
    • Clozapine
    • Codeine; Phenylephrine; Promethazine
    • Codeine; Promethazine
    • Crizotinib
    • Cyclosporine
    • Dapagliflozin
    • Dapagliflozin; Metformin
    • Dapagliflozin; Saxagliptin
    • Dasatinib
    • Degarelix
    • Desflurane
    • Deutetrabenazine
    • Dexmedetomidine
    • Dextromethorphan; Quinidine
    • Dipeptidyl Peptidase-4 Inhibitors
    • Disopyramide
    • Dofetilide
    • Dolasetron
    • Dolutegravir; Rilpivirine
    • Donepezil
    • Donepezil; Memantine
    • Droperidol
    • Dulaglutide
    • Efavirenz
    • Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate
    • Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate
    • Eliglustat
    • Empagliflozin
    • Empagliflozin; Linagliptin
    • Empagliflozin; Linagliptin; Metformin
    • Empagliflozin; Metformin
    • Emtricitabine; Rilpivirine; Tenofovir alafenamide
    • Emtricitabine; Rilpivirine; Tenofovir Disoproxil Fumarate
    • Encorafenib
    • Entrectinib
    • Eribulin
    • Ertugliflozin
    • Ertugliflozin; Metformin
    • Ertugliflozin; Sitagliptin
    • Erythromycin
    • Escitalopram
    • Etrasimod
    • Exenatide
    • Fexinidazole
    • Fingolimod
    • Flecainide
    • Fluconazole
    • Fluoxetine
    • Fluphenazine
    • Fluvoxamine
    • Foscarnet
    • Fostemsavir
    • Gemifloxacin
    • Gemtuzumab Ozogamicin
    • Gilteritinib
    • Givinostat
    • Glasdegib
    • Glimepiride
    • Glipizide
    • Glipizide; Metformin
    • Glyburide
    • Glyburide; Metformin
    • Goserelin
    • Granisetron
    • Halogenated Anesthetics
    • Haloperidol
    • Histrelin
    • Hydroxyzine
    • Ibutilide
    • Iloperidone
    • Incretin Mimetics
    • Inotuzumab Ozogamicin
    • Insulin Aspart
    • Insulin Aspart; Insulin Aspart Protamine
    • Insulin Degludec
    • Insulin Degludec; Liraglutide
    • Insulin Detemir
    • Insulin Glargine
    • Insulin Glargine; Lixisenatide
    • Insulin Glulisine
    • Insulin Lispro
    • Insulin Lispro; Insulin Lispro Protamine
    • Insulin, Inhaled
    • Insulins
    • Isoflurane
    • Isophane Insulin (NPH)
    • Itraconazole
    • Ivosidenib
    • Lansoprazole; Amoxicillin; Clarithromycin
    • Lanthanum Carbonate
    • Lapatinib
    • Lefamulin
    • Lenvatinib
    • Leuprolide
    • Leuprolide; Norethindrone
    • Levofloxacin
    • Linagliptin
    • Linagliptin; Metformin
    • Liraglutide
    • Lithium
    • Lixisenatide
    • Lofexidine
    • Loperamide
    • Loperamide; Simethicone
    • Lopinavir; Ritonavir
    • Macimorelin
    • Magnesium Hydroxide
    • Magnesium Salts
    • Maprotiline
    • Mavorixafor
    • Mefloquine
    • Meglitinides
    • Metformin
    • Metformin; Repaglinide
    • Metformin; Saxagliptin
    • Metformin; Sitagliptin
    • Methadone
    • Metronidazole
    • Midostaurin
    • Mifepristone
    • Mirtazapine
    • Mobocertinib
    • Moxifloxacin
    • Nateglinide
    • Nilotinib
    • Ofloxacin
    • Olanzapine
    • Olanzapine; Fluoxetine
    • Olanzapine; Samidorphan
    • Omeprazole; Sodium Bicarbonate
    • Ondansetron
    • Osilodrostat
    • Osimertinib
    • Oxaliplatin
    • Ozanimod
    • Pacritinib
    • Paliperidone
    • Panobinostat
    • Pasireotide
    • Pazopanib
    • Penicillamine
    • Pentamidine
    • Perphenazine
    • Perphenazine; Amitriptyline
    • Pimavanserin
    • Pioglitazone
    • Pioglitazone; Glimepiride
    • Pioglitazone; Metformin
    • Pitolisant
    • Ponesimod
    • Posaconazole
    • Pramlintide
    • Primaquine
    • Procainamide
    • Prochlorperazine
    • Promethazine
    • Promethazine; Dextromethorphan
    • Promethazine; Phenylephrine
    • Propafenone
    • Quetiapine
    • Quinidine
    • Quinine
    • Quizartinib
    • Rabies Vaccine
    • Ranolazine
    • Regular Insulin
    • Regular Insulin; Isophane Insulin (NPH)
    • Relugolix
    • Relugolix; Estradiol; Norethindrone acetate
    • Remdesivir
    • Repaglinide
    • Ribociclib
    • Ribociclib; Letrozole
    • Rilpivirine
    • Risperidone
    • Romidepsin
    • Rosiglitazone
    • Saquinavir
    • Saxagliptin
    • Selpercatinib
    • Semaglutide
    • Sertraline
    • Sevoflurane
    • SGLT2 Inhibitors
    • Siponimod
    • Sitagliptin
    • Sodium Bicarbonate
    • Sodium Stibogluconate
    • Solifenacin
    • Sorafenib
    • Sotagliflozin
    • Sotalol
    • Sulfonylureas
    • Sunitinib
    • Tacrolimus
    • Tamoxifen
    • Telavancin
    • Tetrabenazine
    • Thiazolidinediones
    • Tirzepatide
    • Tolterodine
    • Toremifene
    • Trazodone
    • Triclabendazole
    • Trifluoperazine
    • Triptorelin
    • Vandetanib
    • Vardenafil
    • Vemurafenib
    • Venlafaxine
    • Vigabatrin
    • Voclosporin
    • Vonoprazan; Amoxicillin; Clarithromycin
    • Voriconazole
    • Vorinostat
    • Ziprasidone

    Level 3 (Moderate)

    • Ampicillin
    • Articaine; Epinephrine
    • Betrixaban
    • Bupivacaine
    • Bupivacaine Liposomal
    • Bupivacaine; Epinephrine
    • Bupivacaine; Meloxicam
    • Carbamazepine
    • Chloroprocaine
    • Cobimetinib
    • Dabigatran
    • Dapsone
    • Digoxin
    • Edoxaban
    • Interferon Alfa-2b
    • Interferon Alfa-n3
    • Interferon Beta-1a
    • Interferon Beta-1b
    • Interferon Gamma-1b
    • Interferons
    • Isoniazid, INH; Pyrazinamide, PZA; Rifampin
    • Isoniazid, INH; Rifampin
    • Lidocaine
    • Lidocaine; Epinephrine
    • Lidocaine; Prilocaine
    • Mepivacaine
    • Peginterferon Alfa-2a
    • Peginterferon Alfa-2b
    • Peginterferon beta-1a
    • Penicillin G Benzathine; Penicillin G Procaine
    • Penicillin G Procaine
    • Phenobarbital
    • Phenobarbital; Hyoscyamine; Atropine; Scopolamine
    • Phenytoin
    • Ponatinib
    • Prilocaine
    • Prilocaine; Epinephrine
    • Primidone
    • Rifampin
    • Ropeginterferon alfa-2b
    • Ropivacaine
    • Succinylcholine
    • Tetracaine
    • Trametinib

    Level 4 (Minor)

    • Acarbose
    • Alpha-glucosidase Inhibitors
    • Miglitol
    • Praziquantel
    Acarbose: (Minor) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents are coadministered. Hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. However, alpha-glucosidase inhibitors are not usually associated with hypoglycemia due to their mechanism and use to lower postprandial blood glucose. [29758] Adagrasib: (Major) Concomitant use of adagrasib and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [68325] Alfuzosin: (Major) Avoid coadministration of chloroquine with alfuzosin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Alfuzosin may prolong the QT interval in a dose-dependent manner. [28229] [28230] [28231] [28261] [65157] [65170] Alogliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Alogliptin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Alogliptin; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Alpha-glucosidase Inhibitors: (Minor) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents are coadministered. Hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. However, alpha-glucosidase inhibitors are not usually associated with hypoglycemia due to their mechanism and use to lower postprandial blood glucose. [29758] Aluminum Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Aluminum Hydroxide; Magnesium Carbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Aluminum Hydroxide; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Aluminum Hydroxide; Magnesium Trisilicate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Amiodarone: (Major) Concomitant use of amiodarone and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Due to the extremely long half-life of amiodarone, a drug interaction is possible for days to weeks after drug discontinuation. [28224] [28229] [28432] [28457] [29758] [65170] Amisulpride: (Major) Avoid coadministration of chloroquine with amisulpride due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Amisulpride causes dose- and concentration-dependent QT prolongation. [28229] [28230] [28231] [65068] [65157] [65170] Amoxicillin; Clarithromycin; Omeprazole: (Major) Avoid coadministration of chloroquine with clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] [65157] [65170] Ampicillin: (Moderate) Administer oral ampicillin 2 hours before or 2 hours after chloroquine. In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. The reduction of ampicillin bioavailability could be attributed to slower gastric emptying and enhancement of gut motility produced by chloroquine. [29758] [61761] Anagrelide: (Major) Avoid coadministration of chloroquine with anagrelide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TdP and ventricular tachycardia have been reported with anagrelide. In addition, dose-related increases in mean QTc and heart rate were observed in healthy subjects. [28229] [28230] [28231] [29758] [30163] [65157] [65170] Antacids: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Apomorphine: (Major) Avoid coadministration of chloroquine with apomorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes; the risk of QT prolongation is increased with higher chloroquine doses. Dose-related QTc prolongation is associated with therapeutic apomorphine exposure. [28229] [28661] [29758] [59321] [65157] [65170] ARIPiprazole: (Major) Avoid coadministration of chloroquine with aripiprazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred during therapeutic use of aripiprazole and following overdose. [28229] [28230] [28231] [29758] [42845] [53394] [60196] [65157] [65170] Arsenic Trioxide: (Major) Avoid coadministration of chloroquine with arsenic trioxide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TdP, QT interval prolongation, and complete atrioventricular block have been reported with arsenic trioxide use. [28226] [28229] [28230] [28231] [65157] [65170] Artemether; Lumefantrine: (Major) Avoid coadministration of chloroquine with artemether; lumefantrine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Artemether; lumefantrine is associated with prolongation of the QT interval. [28229] [28230] [28231] [29758] [35401] [65157] [65170] Articaine; EPINEPHrine: (Moderate) Coadministration of articaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue articaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [28996] Asenapine: (Major) Avoid coadministration of chloroquine with asenapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Asenapine has also been associated with QT prolongation. [28229] [28230] [28231] [29758] [36343] [65157] [65170] Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Atomoxetine: (Major) Avoid coadministration of chloroquine with atomoxetine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred during therapeutic use of atomoxetine and following overdose. [28229] [28230] [28231] [28405] [29758] [59321] [65157] [65170] Azithromycin: (Major) Avoid coadministration of chloroquine with azithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28229] [28230] [28231] [28855] [29758] [43974] [65157] [65170] Bedaquiline: (Major) Avoid coadministration of chloroquine with bedaquiline due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or QTcF interval greater than 500 msec. Bedaquiline prolongs the QT interval. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [52746] [65157] [65170] Betrixaban: (Moderate) Use caution if chloroquine is coadministered with betrixaban due to the potential for increased betrixaban exposure which may increase the risk of bleeding. Betrixaban is a P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [62037] [65210] Bexagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Bismuth Subcitrate Potassium; metroNIDAZOLE; Tetracycline: (Major) Concomitant use of metronidazole and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [36894] [65170] Bismuth Subsalicylate; metroNIDAZOLE; Tetracycline: (Major) Concomitant use of metronidazole and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [36894] [65170] BUPivacaine Liposomal: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [52331] BUPivacaine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [52331] BUPivacaine; EPINEPHrine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [52331] BUPivacaine; Meloxicam: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [52331] Buprenorphine: (Major) Avoid coadministration of chloroquine with buprenorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] [59321] [60270] [65157] [65170] Buprenorphine; Naloxone: (Major) Avoid coadministration of chloroquine with buprenorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] [59321] [60270] [65157] [65170] Cabotegravir; Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170] Calcium Carbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Calcium Carbonate; Famotidine; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Calcium Carbonate; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Calcium Carbonate; Magnesium Hydroxide; Simethicone: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Calcium Carbonate; Simethicone: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Calcium; Vitamin D: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Canagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Canagliflozin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] carBAMazepine: (Moderate) Coadministration of chloroquine and carbamazepine may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and carbamazepine is a strong CYP3A4 inducer. [65210] [65237] [65239] Ceritinib: (Major) Avoid coadministration of chloroquine with ceritinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Interrupt, dose reduce, or discontinue ceritinib if QT prolongation occurs. Ceritinib causes concentration-dependent QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [34353] [57094] [65157] [65170] Chloroprocaine: (Moderate) Coadministration of chloroprocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue chloroprocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29062] chlorproMAZINE: (Major) Avoid coadministration of chloroquine with chlorpromazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Chlorpromazine is associated with an established risk of QT prolongation and TdP. [28229] [28230] [28231] [29758] [43065] [59321] [65157] [65170] Cholera Vaccine: (Major) Administer the live cholera vaccine at least 10 days before beginning antimalarial prophylaxis with chloroquine. The immune response to the cholera vaccine may be diminished when it is administered concomitantly with chloroquine. [60871] Cimetidine: (Major) Avoid concomitant use of chloroquine and cimetidine as cimetidine may inhibit the metabolism of chloroquine, increasing its plasma concentration. [29758] [34335] [34353] [61759] [61760] Ciprofloxacin: (Major) Concomitant use of ciprofloxacin and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [43411] [65170] Cisapride: (Contraindicated) Coadministration of chloroquine with cisapride is contraindicated due to the increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and ventricular arrhythmias, including TdP and death, have been reported with cisapride. [28229] [28230] [28231] [29758] [47221] [65157] [65170] Citalopram: (Major) Avoid coadministration of chloroquine with citalopram due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Citalopram causes dose-dependent QT interval prolongation. [28229] [28230] [28231] [28269] [29758] [65157] [65170] Clarithromycin: (Major) Avoid coadministration of chloroquine with clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] [65157] [65170] Clofazimine: (Major) Concomitant use of clofazimine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [63936] [65170] cloZAPine: (Major) Avoid coadministration of chloroquine with clozapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Treatment with clozapine has been associated with QT prolongation, TdP, cardiac arrest, and sudden death. [28229] [28230] [28231] [28262] [29758] [65157] [65170] Cobimetinib: (Moderate) Concurrent use of chloroquine and cobimetinib is not recommended as there is an increased risk of retinal toxicity. [29758] [60281] Codeine; Phenylephrine; Promethazine: (Major) Concomitant use of promethazine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170] Codeine; Promethazine: (Major) Concomitant use of promethazine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170] Crizotinib: (Major) Avoid coadministration of chloroquine with crizotinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs. Crizotinib can cause concentration-dependent QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28231] [29758] [45458] [65157] [65170] cycloSPORINE: (Major) Closely monitor the serum cyclosporine concentrations and adjust the dose of cyclosporine as appropriate after starting or stopping chloroquine therapy. Sudden increases in cyclosporine concentrations have been reported after the addition of chloroquine. Monitor patients for cyclosporine-related adverse events such as nephrotoxicity or hepatic toxicity. Discontinue chloroquine if necessary. [29758] Dabigatran: (Moderate) Use caution if chloroquine is coadministered with dabigatran due to the potential for increased dabigatran exposure which may increase the risk of bleeding. Dabigatran is a P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [42121] [65210] Dapagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Dapagliflozin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Dapagliflozin; sAXagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Dapsone: (Moderate) Coadministration of dapsone with chloroquine may increase the risk of developing methemoglobinemia. Advise patients to discontinue treatment and seek immediate medical attention with any signs or symptoms of methemoglobinemia. [60612] Dasatinib: (Major) Avoid coadministration of chloroquine with dasatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. In vitro studies have shown that dasatinib has the potential to prolong the QT interval. [28229] [28230] [28231] [29758] [32387] [65157] [65170] Degarelix: (Major) Avoid coadministration of chloroquine with degarelix due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., degarelix) may also prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [46869] [65157] [65170] Desflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157] [65170] Deutetrabenazine: (Major) Avoid coadministration of chloroquine with deutetrabenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Deutetrabenazine may prolong the QT interval, but the degree of QT prolongation is not clinically significant when deutetrabenazine is administered within the recommended dosage range. [28229] [29758] [61845] [65157] [65170] dexmedeTOMIDine: (Major) Concomitant use of dexmedetomidine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [67509] Dextromethorphan; quiNIDine: (Major) Avoid coadministration of chloroquine with quinidine due to the increased risk of QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinidine administration is also associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [42280] [47357] [65157] [65170] Digoxin: (Moderate) Monitor serum digoxin concentrations in patients receiving digoxin and chloroquine as coadministration may result in increased serum digoxin concentrations. Digoxin serum concentrations have been reported to increase when hydroxychloroquine was added. Although this interaction has not been reported with chloroquine, chloroquine may similarly increase the plasma concentration of digoxin. [41806] [60957] Dipeptidyl Peptidase-4 Inhibitors: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Disopyramide: (Major) Avoid coadministration of chloroquine with disopyramide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Disopyramide administration is associated with QT prolongation and TdP. [28228] [28229] [28230] [28231] [29758] [65157] [65170] Dofetilide: (Major) Avoid coadministration of chloroquine with dofetilide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Dofetilide, a Class III antiarrhythmic agent, is associated with a well-established risk of QT prolongation and TdP. [28221] [28229] [28230] [28231] [28432] [28457] [29758] [65157] [65170] Dolasetron: (Major) Avoid coadministration of chloroquine with dolasetron due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Dolasetron has been associated with a dose-dependent prolongation of the QT, PR, and QRS intervals on an electrocardiogram. [28229] [28230] [28231] [28308] [29758] [34353] [42844] [65157] [65170] Dolutegravir; Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170] Donepezil: (Major) Avoid coadministration of chloroquine with donepezil due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] [65157] [65170] Donepezil; Memantine: (Major) Avoid coadministration of chloroquine with donepezil due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] [65157] [65170] Dronedarone: (Contraindicated) Coadministration of chloroquine with dronedarone is contraindicated due to the increased risk of QT prolongation. Dronedarone administration is associated with a dose-related increase in the QTc interval. The increase in QTc is approximately 10 milliseconds at doses of 400 mg twice daily (the FDA-approved dose) and up to 25 milliseconds at doses of 1,600 mg twice daily. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [36101] [65157] [65170] droPERidol: (Major) Avoid coadministration of chloroquine with droperidol due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect. Droperidol administration is associated with an established risk for QT prolongation and torsade de pointes (TdP). Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28231] [28235] [28236] [28237] [28737] [29758] [51289] [59321] [65157] [65170] Dulaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Edoxaban: (Moderate) Use caution if chloroquine is coadministered with edoxaban due to the potential for increased edoxaban exposure which may increase the risk of bleeding. Edoxaban is a P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [58685] [65210] Efavirenz: (Major) Avoid coadministration of chloroquine with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QTc prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170] Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of chloroquine with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QTc prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170] Efavirenz; lamiVUDine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of chloroquine with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QTc prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170] Eliglustat: (Major) Avoid coadministration of chloroquine with eliglustat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Eliglustat is predicted to cause PR, QRS, and/or QT prolongation at significantly elevated plasma concentrations. [28229] [28230] [28231] [29758] [57803] [65157] [65170] Empagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Empagliflozin; Linagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Empagliflozin; Linagliptin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Empagliflozin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170] Emtricitabine; Rilpivirine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170] Encorafenib: (Major) Avoid coadministration of chloroquine with encorafenib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Encorafenib has been associated with dose-dependent QT prolongation. [28229] [28230] [28231] [29758] [63317] [65157] [65170] Entrectinib: (Major) Avoid coadministration of chloroquine with entrectinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Entrectinib has been associated with QT prolongation. [28229] [28230] [28231] [29758] [64567] [65157] [65170] eriBULin: (Major) Avoid coadministration of chloroquine with eribulin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Eribulin has been associated with QT prolongation. [28229] [28230] [28231] [29758] [42449] [65157] [65170] Ertugliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Ertugliflozin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Ertugliflozin; SITagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Erythromycin: (Major) Concomitant use of chloroquine and erythromycin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [43258] [59321] [65157] [65170] Escitalopram: (Major) Concomitant use of chloroquine and escitalopram increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [28270] [29758] [65157] [65170] Etrasimod: (Major) Concomitant use of etrasimod and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Etrasimod has a limited effect on the QT/QTc interval at therapeutic doses but may cause bradycardia and atrioventricular conduction delays which may increase the risk for TdP in patients with a prolonged QT/QTc interval. [28229] [29758] [65170] [69114] Exenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Fexinidazole: (Major) Concomitant use of fexinidazole and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [66812] Fingolimod: (Major) Avoid coadministration of chloroquine with fingolimod due to the increased risk of QT prolongation. If use together is necessary, overnight monitoring with continuous ECG in a medical facility is advised after the first dose of fingolimod; monitor ECG closely throughout therapy, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Fingolimod initiation results in decreased heart rate and may prolong the QT interval. Fingolimod has not been studied in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with bradycardia. [28229] [28230] [28231] [29758] [65157] [65170] Flecainide: (Major) Avoid coadministration of chloroquine with flecainide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Flecainide is a Class IC antiarrhythmic associated with a possible risk for QT prolongation and/or TdP; flecainide increases the QT interval, but largely due to prolongation of the QRS interval. Although causality for TdP has not been established for flecainide, patients receiving concurrent drugs that have the potential for QT prolongation may have an increased risk of developing proarrhythmias. [23774] [28229] [28230] [28231] [28752] [29758] [51070] [65157] [65170] Fluconazole: (Major) Concomitant use of chloroquine and fluconazole increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [28674] [29758] [60686] [65157] [65170] FLUoxetine: (Major) Concomitant use of chloroquine and fluoxetine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [32127] [44058] [44059] [65157] [65170] fluPHENAZine: (Major) Avoid coadministration of chloroquine with fluphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Fluphenazine is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [59321] [65157] [65170] fluvoxaMINE: (Major) Avoid coadministration of chloroquine with fluvoxamine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP has been reported during fluvoxamine postmarketing use. [28229] [28230] [28231] [29758] [50507] [65157] [65170] Foscarnet: (Major) Avoid coadministration of chloroquine with foscarnet due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Both QT prolongation and TdP have been reported during postmarketing use of foscarnet. [28229] [28230] [28231] [28377] [29758] [65157] [65170] Fostemsavir: (Major) Avoid coadministration of chloroquine with fostemsavir due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of fostemsavir (2,400 mg twice daily, four times the recommended daily dose) have been shown to cause QT prolongation. Fostemsavir causes dose-dependent QT prolongation. [28229] [29758] [65157] [65170] [65666] Gemifloxacin: (Major) Avoid coadministration of chloroquine with gemifloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Gemifloxacin may prolong the QT interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with increasing gemifloxacin dose; therefore, do not exceed the recommended dose, especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. [28229] [28230] [28231] [28419] [28420] [28424] [29758] [65157] [65170] Gemtuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with gemtuzumab due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. [28229] [28230] [28231] [29758] [62292] [65157] [65170] Gilteritinib: (Major) Avoid coadministration of chloroquine with gilteritinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Gilteritinib has been associated with QT prolongation. [28229] [28230] [28231] [29758] [63787] [65157] [65170] Givinostat: (Major) Concomitant use of givinostat and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. The degree of QT prolongation associated with givinostat is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 5 times the maximum recommended dose. [28229] [29758] [65170] [70477] Glasdegib: (Major) Avoid coadministration of chloroquine with glasdegib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. [28229] [28230] [28231] [29758] [63777] [65157] [65170] Glimepiride: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] glipiZIDE: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] glipiZIDE; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] glyBURIDE: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] glyBURIDE; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Goserelin: (Major) Avoid coadministration of chloroquine with goserelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., goserelin) may also prolong the QT/QTc interval. [28229] [28230] [28231] [28592] [29758] [65157] [65170] Granisetron: (Major) Avoid coadministration of chloroquine with granisetron due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Granisetron has been associated with QT prolongation. [28229] [28230] [28231] [29758] [31723] [65157] [65170] Halogenated Anesthetics: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157] [65170] Haloperidol: (Major) Avoid coadministration of chloroquine with haloperidol due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP have been observed during haloperidol treatment. Excessive doses (particularly in the overdose setting) or IV administration of haloperidol may be associated with a higher risk of QT prolongation. [23500] [23779] [28229] [28230] [28231] [28307] [28415] [29758] [59321] [65157] [65170] Histrelin: (Major) Avoid coadministration of chloroquine with histrelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., histrelin) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [30369] [65157] [65170] hydrOXYzine: (Major) Concomitant use of hydroxyzine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [47129] [61470] [65157] [65170] Ibutilide: (Major) Avoid coadministration of chloroquine with ibutilide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated. The potential for proarrhythmic events with ibutilide increases with the use of other drugs that prolong the QT interval. [28229] [28230] [28231] [29758] [41830] [65157] [65170] Iloperidone: (Major) Avoid coadministration of chloroquine with iloperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Iloperidone has also been associated with QT prolongation. [28229] [28230] [28231] [29758] [36146] [65157] [65170] Incretin Mimetics: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Inotuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with inotuzumab due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Inotuzumab has also been associated with QT interval prolongation. [28229] [28230] [28231] [29758] [62245] [65157] [65170] Insulin Aspart: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Aspart; Insulin Aspart Protamine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Degludec: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Degludec; Liraglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Detemir: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Glargine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Glargine; Lixisenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Glulisine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Lispro: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin Lispro; Insulin Lispro Protamine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulin, Inhaled: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Insulins: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Interferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Interferon Alfa-n3: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Interferon Beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Interferon Beta-1b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Interferon Gamma-1b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Interferons: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Isoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157] [65170] Isoniazid, INH; Pyrazinamide, PZA; rifAMPin: (Moderate) Monitor patients more frequently for signs of reduced chloroquine effects if administered with rifampin. Coadministration may decrease the exposure of chloroquine. Chloroquine may be a CYP3A4 substrate in vitro, and rifampin is a strong CYP3A4 inducer. [65210] Isoniazid, INH; rifAMPin: (Moderate) Monitor patients more frequently for signs of reduced chloroquine effects if administered with rifampin. Coadministration may decrease the exposure of chloroquine. Chloroquine may be a CYP3A4 substrate in vitro, and rifampin is a strong CYP3A4 inducer. [65210] Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Itraconazole: (Major) Avoid coadministration of chloroquine with itraconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Itraconazole has also been associated with prolongation of the QT interval. [27983] [28229] [28230] [28231] [29758] [40233] [57441] [63821] [65157] [65170] Ivosidenib: (Major) Avoid coadministration of chloroquine with ivosidenib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [65157] [65170] Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and chloroquine due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. [27982] [28229] [29758] [65170] [67231] Lansoprazole; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of chloroquine with clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] [65157] [65170] Lanthanum Carbonate: (Major) Oral compounds known to interact with antacids, like chloroquine, should not be taken within 4 hours of dosing with lanthanum carbonate. If these agents are used concomitantly, space the dosing intervals appropriately. Monitor serum concentrations and clinical condition. [29758] [30284] [30285] [44406] Lapatinib: (Major) Avoid coadministration of chloroquine with lapatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience with lapatinib. [28229] [28230] [28231] [29758] [33192] [65157] [65170] Lefamulin: (Major) Avoid coadministration of chloroquine with lefamulin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Lefamulin has a concentration dependent QTc prolongation effect. The potential to prolong the QT interval of the ECG between lefamulin and other drugs that effect cardiac conduction is unknown. [28229] [28230] [28231] [29758] [64576] [65157] [65170] Lenvatinib: (Major) Avoid coadministration of chloroquine with lenvatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Prolongation of the QT interval has been reported with lenvatinib therapy. [28229] [28230] [28231] [29758] [58782] [65157] [65170] Leuprolide: (Major) Avoid coadministration of chloroquine with leuprolide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., leuprolide) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170] Leuprolide; Norethindrone: (Major) Avoid coadministration of chloroquine with leuprolide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., leuprolide) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170] levoFLOXacin: (Major) Concomitant use of levofloxacin and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [28421] [29758] [61195] [63729] [65157] [65170] Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and chloroquine due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. [27982] [28229] [29758] [65170] [67231] Lidocaine: (Moderate) Coadministration of lidocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue lidocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [43383] Lidocaine; EPINEPHrine: (Moderate) Coadministration of lidocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue lidocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [43383] Lidocaine; Prilocaine: (Moderate) Coadministration of lidocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue lidocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [43383] (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue prilocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29064] Linagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Linagliptin; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Liraglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Lithium: (Major) Concomitant use of lithium and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [59809] [59810] [59811] [65157] [65170] Lixisenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Lofexidine: (Major) Avoid coadministration of chloroquine with lofexidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Lofexidine also prolongs the QT interval. [28229] [28230] [28231] [29758] [63161] [65157] [65170] Loperamide: (Major) Avoid coadministration of chloroquine with loperamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170] Loperamide; Simethicone: (Major) Avoid coadministration of chloroquine with loperamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170] Lopinavir; Ritonavir: (Major) Avoid coadministration of chloroquine and lopinavir due the risk of additive QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); fatalities have been reported. The risk of QT prolongation is increased with higher chloroquine doses. Lopinavir is also associated with QT prolongation. [28229] [28230] [28231] [28341] [29758] [65157] [65170] Macimorelin: (Major) Avoid coadministration of chloroquine with macimorelin due to the increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia. Allow a sufficient washout period before starting macimorelin. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Treatment with macimorelin has been associated with an increase in the corrected QT (QTc) interval. [28229] [28230] [28231] [29758] [62723] [65157] [65170] Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Magnesium Salts: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285] Maprotiline: (Major) Avoid coadministration of chloroquine with maprotiline due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. [28225] [28229] [28230] [28231] [29758] [51740] [65157] [65170] Mavorixafor: (Major) Concomitant use of mavorixafor and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. The degree of QT prolongation associated with mavorixafor is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 2 times the maximum recommended dose. [28229] [29758] [65170] [70577] Mefloquine: (Major) Avoid coadministration of chloroquine with mefloquine due to the increased risk of QT prolongation and seizures. These drugs are both analogs of quinine. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. Also, both drugs may lower the seizure threshold. [28229] [28230] [28231] [28301] [29758] [65157] [65170] Meglitinides: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Mepivacaine: (Moderate) Coadministration of mepivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue mepivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29100] metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] metFORMIN; Repaglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] metFORMIN; sAXagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] metFORMIN; SITagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Methadone: (Major) Avoid coadministration of chloroquine with methadone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Methadone is considered to be associated with an increased risk for QT prolongation and TdP, especially at higher doses (more than 200 mg/day but averaging approximately 400 mg/day in adult patients). Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. [28229] [28230] [28231] [28319] [28320] [28321] [28322] [29758] [33136] [65157] [65170] metroNIDAZOLE: (Major) Concomitant use of metronidazole and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [36894] [65170] Midostaurin: (Major) Avoid coadministration of chloroquine with midostaurin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation was reported in patients who received midostaurin in clinical trials. [28229] [28230] [28231] [29758] [61906] [65157] [65170] miFEPRIStone: (Major) Concomitant use of mifepristone and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [48697] [65157] [65170] Miglitol: (Minor) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents are coadministered. Hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. However, alpha-glucosidase inhibitors are not usually associated with hypoglycemia due to their mechanism and use to lower postprandial blood glucose. [29758] Mirtazapine: (Major) Concomitant use of chloroquine and mirtazapine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [40942] [65157] [65170] Mobocertinib: (Major) Concomitant use of mobocertinib and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [66990] Moxifloxacin: (Major) Avoid coadministration of chloroquine with moxifloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinolones have been associated with a risk of QT prolongation. TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. [28229] [28230] [28231] [28423] [29758] [59321] [65157] [65170] Nateglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Nilotinib: (Major) Avoid coadministration of chloroquine with nilotinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Sudden death and QT interval prolongation have occurred in patients who received nilotinib therapy. [28229] [28230] [28231] [29758] [58766] [65157] [65170] Ofloxacin: (Major) Concomitant use of ofloxacin and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [30738] [65157] [65170] OLANZapine: (Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28229] [28230] [28231] [28785] [29758] [32732] [32734] [32745] [65157] [65170] OLANZapine; FLUoxetine: (Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28229] [28230] [28231] [28785] [29758] [32732] [32734] [32745] [65157] [65170] (Major) Concomitant use of chloroquine and fluoxetine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [32127] [44058] [44059] [65157] [65170] OLANZapine; Samidorphan: (Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28229] [28230] [28231] [28785] [29758] [32732] [32734] [32745] [65157] [65170] Omeprazole; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Ondansetron: (Major) Concomitant use of ondansetron and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Do not exceed 16 mg of IV ondansetron in a single dose; the degree of QT prolongation associated with ondansetron significantly increases above this dose. [28229] [28230] [28231] [29758] [31266] [32722] [34335] [34353] [65157] [65170] Osilodrostat: (Major) Avoid coadministration of chloroquine with osilodrostat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Osilodrostat is associated with dose-dependent QT prolongation. [28229] [28230] [28231] [29758] [65098] [65157] [65170] Osimertinib: (Major) Avoid coadministration of chloroquine with osimertinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if QT prolongation occurs. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [60297] [65157] [65170] Oxaliplatin: (Major) Avoid coadministration of chloroquine with oxaliplatin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and ventricular arrhythmias including fatal TdP have been reported with oxaliplatin use in postmarketing experience. [28229] [28230] [28231] [28415] [29758] [41958] [65157] [65170] Ozanimod: (Major) Avoid coadministration of chloroquine with ozanimod due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. [28229] [29758] [65157] [65169] [65170] Pacritinib: (Major) Concomitant use of pacritinib and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [67427] Paliperidone: (Major) Avoid coadministration of chloroquine with paliperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Paliperidone has been associated with QT prolongation; TdP and ventricular fibrillation have been reported in the setting of overdose. [28229] [28230] [28231] [29758] [40936] [65157] [65170] Panobinostat: (Major) Avoid coadministration of chloroquine with panobinostat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has also been reported with panobinostat. [28229] [28230] [28231] [29758] [58821] [65157] [65170] Pasireotide: (Major) Avoid coadministration of chloroquine with pasireotide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred with pasireotide at therapeutic and supra-therapeutic doses. [28229] [28230] [28231] [29758] [65157] [65170] PAZOPanib: (Major) Avoid coadministration of chloroquine with pazopanib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pazopanib has also been reported to prolong the QT interval. [28229] [28230] [28231] [29758] [37098] [65157] [65170] Peginterferon Alfa-2a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Peginterferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] Peginterferon beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] penicillAMINE: (Major) Do not use penicillamine concurrently with antimalarials due to an increased risk of severe hematologic and renal adverse reactions. [28834] Penicillin G Benzathine; Penicillin G Procaine: (Moderate) Coadministration of penicillin G procaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue penicillin G procaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [31217] Penicillin G Procaine: (Moderate) Coadministration of penicillin G procaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue penicillin G procaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [31217] Pentamidine: (Major) Avoid coadministration of chloroquine with pentamidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Systemic pentamidine has also been associated with QT prolongation. [23620] [23778] [28229] [28230] [28231] [28419] [28879] [29758] [65157] [65170] Perphenazine: (Major) Avoid coadministration of chloroquine with perphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Perphenazine is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170] Perphenazine; Amitriptyline: (Major) Avoid coadministration of chloroquine with perphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Perphenazine is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170] PHENobarbital: (Moderate) Coadministration of chloroquine and phenobarbital may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. [65210] [65237] [65239] PHENobarbital; Hyoscyamine; Atropine; Scopolamine: (Moderate) Coadministration of chloroquine and phenobarbital may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. [65210] [65237] [65239] Phenytoin: (Moderate) Coadministration of chloroquine and phenytoin may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenytoin is a strong CYP3A4 inducer. [65210] [65237] [65239] Pimavanserin: (Major) Avoid coadministration of chloroquine with pimavanserin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pimavanserin also prolongs the QT interval. [28229] [28230] [28231] [29758] [60748] [65157] [65170] Pimozide: (Contraindicated) Coadministration of chloroquine with pimozide is contraindicated due to the increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pimozide is associated with a well-established risk of QT prolongation and TdP. [28225] [28229] [28230] [28231] [29758] [43463] [65170] Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Pioglitazone; Glimepiride: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Pioglitazone; metFORMIN: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Pitolisant: (Major) Avoid coadministration of chloroquine with pitolisant due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pitolisant also prolongs the QT interval. [28229] [28230] [28231] [29758] [64562] [65157] [65170] PONATinib: (Moderate) Concurrent use of chloroquine and ponatinib is not recommended as there is an increased risk of retinal toxicity. [29758] [52603] Ponesimod: (Major) Avoid coadministration of chloroquine with ponesimod due to the increased risk of QT prolongation and torsade de pointes (TdP). If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and TdP; the risk of QT prolongation is increased with higher chloroquine doses. Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. [28229] [29758] [65170] [66527] Posaconazole: (Major) Avoid coadministration of chloroquine with posaconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Posaconazole has been associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [32723] [65157] [65170] Pramlintide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including pramlintide, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Praziquantel: (Minor) Monitor for altered clinical response to praziquantel if concomitant use with chloroquine is necessary. Concomitant use has been observed to decrease praziquantel exposure which may reduce its efficacy. [27846] [29758] Prilocaine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue prilocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29064] Prilocaine; EPINEPHrine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue prilocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29064] Primaquine: (Major) Avoid coadministration of chloroquine with primaquine due to the increased risk of QT prolongation or other toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Primaquine may also prolong the QT interval. [28229] [28230] [28231] [29758] [41984] [65157] [65170] Primidone: (Moderate) Monitor patients more frequently for signs of reduced chloroquine effects if administered with primidone. Coadministration may decrease the exposure of chloroquine. Chloroquine may be a CYP3A4 substrate in vitro, and primidone is a strong CYP3A4 inducer. [65210] Procainamide: (Major) Avoid coadministration of chloroquine with procainamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Procainamide is associated with a well-established risk of QT prolongation and TdP. [28229] [28230] [28231] [29758] [65157] [65170] Prochlorperazine: (Major) Avoid coadministration of chloroquine with prochlorperazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Prochlorperazine is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170] Promethazine: (Major) Concomitant use of promethazine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170] Promethazine; Dextromethorphan: (Major) Concomitant use of promethazine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170] Promethazine; Phenylephrine: (Major) Concomitant use of promethazine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170] Propafenone: (Major) Concomitant use of propafenone and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [28287] [29758] [65157] [65170] QUEtiapine: (Major) Concomitant use of quetiapine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29118] [29758] [33068] [33072] [33074] [65157] [65170] quiNIDine: (Major) Avoid coadministration of chloroquine with quinidine due to the increased risk of QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinidine administration is also associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [42280] [47357] [65157] [65170] quiNINE: (Major) Avoid coadministration of chloroquine with quinine due to the increased risk of QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinine has been associated with QT prolongation and rare cases of TdP. [28229] [28230] [28231] [29758] [31403] [65157] [65170] Quizartinib: (Major) Concomitant use of quizartinib and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [65170] [69220] Rabies Vaccine: (Major) If administered concurrently, antimalarials can impair the immunologic response to the rabies vaccine, thereby, decreasing its protective effect. If possible, administration of antimalarials should be avoided during use of the rabies vaccine for postexposure prophylaxis. When antimalarials must be administered to persons also receiving the rabies vaccine for postexposure prophylaxis, a serum rabies antibody titer should be obtained on day 14 (day of the 4th vaccination) to ensure an acceptable antibody response has been induced. [40848] [40849] Ranolazine: (Major) Avoid coadministration of chloroquine with ranolazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval. [28229] [28230] [28231] [29758] [31938] [65157] [65170] Regular Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Regular Insulin; Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Relugolix: (Major) Avoid coadministration of chloroquine with relugolix due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., relugolix) may also prolong the QT/QTc interval. [28229] [29758] [65157] [65170] [66183] Relugolix; Estradiol; Norethindrone acetate: (Major) Avoid coadministration of chloroquine with relugolix due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., relugolix) may also prolong the QT/QTc interval. [28229] [29758] [65157] [65170] [66183] Remdesivir: (Major) Coadministration of remdesivir and chloroquine is not recommended. Based on data from cell culture experiments, the intracellular metabolic activation and antiviral activity of remdesivir may be antagonized by chloroquine phosphate in a dose-dependent manner. [65365] [66063] Repaglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Ribociclib: (Major) Avoid coadministration of chloroquine with ribociclib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] [65157] [65170] Ribociclib; Letrozole: (Major) Avoid coadministration of chloroquine with ribociclib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] [65157] [65170] rifAMPin: (Moderate) Monitor patients more frequently for signs of reduced chloroquine effects if administered with rifampin. Coadministration may decrease the exposure of chloroquine. Chloroquine may be a CYP3A4 substrate in vitro, and rifampin is a strong CYP3A4 inducer. [65210] Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170] risperiDONE: (Major) Avoid coadministration of chloroquine with risperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Risperidone has been associated with a possible risk for QT prolongation and/or TdP, primarily in the overdose setting. [22256] [28229] [28414] [29758] [59321] [65157] [65170] romiDEPsin: (Major) Avoid coadministration of chloroquine with romidepsin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Romidepsin has been reported to prolong the QT interval. [28229] [28230] [28231] [29758] [37292] [65157] [65170] Ropeginterferon alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an increased risk of retinal toxicity. [29758] [47391] ROPivacaine: (Moderate) Coadministration of ropivacaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue ropivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [52330] Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Saquinavir: (Major) Avoid coadministration of chloroquine with saquinavir boosted with ritonavir due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as TdP. [28229] [28230] [28231] [28995] [29758] [65157] [65170] sAXagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Selpercatinib: (Major) Avoid coadministration of chloroquine with selpercatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Concentration-dependent QT prolongation has been observed with selpercatinib therapy. [28229] [29758] [65157] [65170] [65387] Semaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Sertraline: (Major) Concomitant use of sertraline and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. The degree of QT prolongation associated with sertraline is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 2 times the maximum recommended dose. [28229] [28343] [29758] [64391] [64392] [64394] [64396] [65157] [65170] Sevoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157] [65170] SGLT2 Inhibitors: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Siponimod: (Major) Avoid coadministration of chloroquine with siponimod due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. [28229] [28230] [28231] [29758] [64031] [65157] [65170] SITagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] Sodium Stibogluconate: (Major) Concomitant use of sodium stibogluconate and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [64608] [65170] Solifenacin: (Major) Avoid coadministration of chloroquine with solifenacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP has been reported with postmarketing use, although causality was not determined. [28229] [28230] [28231] [29758] [30515] [65157] [65170] SORAfenib: (Major) Avoid coadministration of chloroquine with sorafenib due to the risk of additive QT prolongation. If concomitant use is unavoidable, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Sorafenib is also associated with QTc prolongation. [28229] [28230] [28231] [29758] [31832] [65157] [65170] Sotagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Sotalol: (Major) Concomitant use of sotalol and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [28234] [29758] [65157] [65170] Succinylcholine: (Moderate) Concomitant use of succinylcholine and chloroquine may prolong neuromuscular blockade. [42039] Sulfonylureas: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] SUNItinib: (Major) Avoid coadministration of chloroquine with sunitinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Sunitinib can also prolong the QT interval. [28229] [28230] [28231] [29758] [65157] [65170] Tacrolimus: (Major) Avoid coadministration of chloroquine with tacrolimus due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Tacrolimus may prolong the QT interval and cause TdP. [28229] [28230] [28231] [28611] [29758] [55401] [60497] [65157] [65170] Tamoxifen: (Major) Concomitant use of tamoxifen and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [61872] [63589] [65157] [65170] Telavancin: (Major) Avoid coadministration of chloroquine with telavancin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Telavancin has also been associated with QT prolongation. [28229] [28230] [28231] [29758] [36615] [65157] [65170] Tetrabenazine: (Major) Avoid coadministration of chloroquine with tetrabenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Tetrabenazine causes a small increase in the corrected QT interval (QTc). [28229] [28230] [28231] [29758] [34389] [65157] [65170] Tetracaine: (Moderate) Coadministration of tetracaine with oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue tetracaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [31353] Thiazolidinediones: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Thioridazine: (Contraindicated) Coadministration of chloroquine with thioridazine is contraindicated due to the increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Thioridazine is associated with a well-established risk of QT prolongation and TdP. [28225] [28229] [28230] [28231] [28293] [29758] [65170] Tirzepatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] Tolterodine: (Major) Avoid coadministration of chloroquine with tolterodine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. [28229] [28230] [28231] [29758] [31112] [65157] [65170] Toremifene: (Major) Avoid coadministration of chloroquine with toremifene due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner. [28229] [28230] [28231] [28822] [29758] [65157] [65170] Trametinib: (Moderate) Concurrent use of chloroquine and trametinib is not recommended as there is an increased risk of retinal toxicity. [29758] [60372] traZODone: (Major) Concomitant use of trazodone and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [38831] [63609] [65157] [65170] Triclabendazole: (Major) Concomitant use of triclabendazole and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [29758] [63962] [65170] Trifluoperazine: (Major) Avoid coadministration of chloroquine with trifluoperazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Trifluoperazine is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170] Triptorelin: (Major) Avoid coadministration of chloroquine with triptorelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e., triptorelin) may prolong the QT interval. [28229] [28230] [28231] [29758] [45411] [65157] [65170] Vandetanib: (Major) Avoid coadministration of chloroquine with vandetanib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Vandetanib can prolong the QT interval in a concentration-dependent manner; TdP and sudden death have been reported in patients receiving vandetanib. [28229] [28230] [28231] [29758] [43901] [65157] [65170] Vardenafil: (Major) Concomitant use of vardenafil and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28216] [28229] [29758] [41124] [59321] [65157] [65170] Vemurafenib: (Major) Avoid coadministration of chloroquine with vemurafenib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Vemurafenib has also been associated with QT prolongation. [28229] [28230] [28231] [29758] [45335] [59321] [65157] [65170] Venlafaxine: (Major) Concomitant use of venlafaxine and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28229] [28230] [28231] [29758] [33715] [65157] [65170] Vigabatrin: (Major) Vigabatrin should not be used with chloroquine due to potential retinal toxicity associated with both drugs, unless the benefits of treatment clearly outweigh the risks. [29758] [36250] Voclosporin: (Major) Avoid concomitant use of chloroquine and voclosporin due to the risk of additive QT prolongation. Monitor ECG and electrolytes and avoid other non-essential QT prolonging drugs if use together is required. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Voclosporin has been associated with QT prolongation at supratherapeutic doses. [28229] [29758] [65157] [65170] [66336] Vonoprazan; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of chloroquine with clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] [65157] [65170] Voriconazole: (Major) Avoid coadministration of chloroquine with voriconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Voriconazole has been associated with QT prolongation and rare cases of TdP. [28158] [28229] [28230] [28231] [29758] [65157] [65170] Vorinostat: (Major) Avoid coadministration of chloroquine with vorinostat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Vorinostat therapy is also associated with a risk of QT prolongation. [28229] [28230] [28231] [29758] [32789] [65157] [65170] Ziprasidone: (Major) Avoid coadministration of chloroquine with ziprasidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of TdP in patients with multiple confounding factors. [28229] [28230] [28231] [28233] [29758] [65157] [65170]
    Revision Date: 09/27/2024, 03:59:00 AM

    References

    22256 - Risperdal Consta (risperidone long-acting injection) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2021 Feb.23500 - Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.23620 - Green PT, Reents S, Harman E, et al. Pentamidine-induced torsades de pointes in a renal tranplant recipient with Pneumocystis carinii pneumonia. S Med J 1990;83:481-4.23774 - Lui HK, Lee G, Dietrich P, et al. Flecainide-induced QT prolongation and ventricular tachycardia. Am Heart J 1982;103:567-9.23778 - Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-6.23779 - Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol-induced torsades de pointes. Chest 1990;98:482-3.27846 - Masimirembwa CM, Naik YS, Hasler JA. The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and humans. Biopharm Drug Dispos 1994;15:33-43.27982 - Ketoconazole tablets package insert. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2017 Sept.27983 - Sporanox (itraconazole) capsules package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Feb.28158 - VFEND (voriconazole) tablets, suspension, and injection package insert. New York, NY: Pfizer Inc; 2024 Aug.28216 - Levitra (vardenafil) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2023 Mar.28221 - Tikosyn (dofetilide) package insert. New York, NY: Pfizer Labs; 2019 Aug.28224 - Pacerone (amiodarone) tablets package insert. Maple Grove, MN: Upsher-Smith Laboratories, LLC.; 2018 Nov.28225 - CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web at http://www.crediblemeds.org.28226 - Trisenox (arsenic trioxide) package insert. Frazer, PA: Cephalon, Inc; 2010 Jun.28228 - Norpace and Norpace CR (disopyramide) package insert. Chicago, IL: G.D. Searle LLC division of Pfizer Inc; 2016 Aug.28229 - Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.28230 - Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. Postgrad Med J 2001;77:344, 352-3.28231 - Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5.28233 - Geodon (ziprasidone) package insert. New York, NY: Pfizer: 2021 May.28234 - Betapace (sotalol) package insert. Wayne, NJ: Berlex Laboratories; 2011 Aug.28235 - Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? J Emerg Med 2003;24:441-7.28236 - Kao LW, Kirk MA, Evers SJ, et al. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003;41:546-58.28237 - Food and Drug Administration Press Office. FDA strengthens warnings for droperidol. FDA Talk Paper. December 5, 2001. Accessed: April 16, 2004. Available on the World Wide Web at: http://www.fda.gov/bbs/topics/answers/2001/ans01123.html28238 - Biaxin (clarithromycin) package insert. North Chicago, IL: AbbVie, Inc.; 2019 Sep.28261 - Uroxatral (alfuzosin extended-release tablets) package insert. St. Michael, Barbados: Concordia Pharmaceuticals, INC.; 2015 May.28262 - Clozaril (clozapine) tablets package insert. Rosemont, PA: HLS Therapeutics (USA), Inc.; 2024 Sept.28269 - Celexa (citalopram) tablets package insert. North Chicago, IL: AbbVie Inc.; 2023 Oct.28270 - Lexapro (escitalopram) package insert. North Chicago, IL: Abbvie, Inc.; 2024 Apr.28287 - Rythmol SR (propafenone hydrochloride) capsule extended release package insert. Research Triangle Park, NC: GlaxoSmithKline; 2018 Nov.28293 - Thioridazine package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2016 Nov.28301 - Mefloquine hydrochloride package insert. North Wales PA: Teva Pharmaceuticals USA Inc.; 2019 Mar.28307 - Haldol (haloperidol) injection for immediate release package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2020 Feb.28308 - Anzemet (dolasetron mesylate) tablets package insert. Parsippany, NJ: Validus Pharmaceuticals LLC; 2021 June.28319 - Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-5.28320 - Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103:321-4.28321 - Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.28322 - Gil M, Sala M, Anguera I, et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92:995-7.28341 - Kaletra (lopinavir; ritonavir) tablet and solution package insert. North Chicago, IL: AbbVie Inc; 2020 Oct.28343 - Zoloft (sertraline) package insert. Morgantown, WV: Viatris Specialty LLC; 2023 Aug.28377 - Foscavir (foscarnet) package insert. Lake Forest, IL: Hospira, Inc.; 2020 Oct.28405 - Strattera (atomoxetine) package insert. Indianapolis, IN: Eli Lilly and Company; 2022 Jan.28414 - Risperdal (risperidone tablets, oral solution, and orally disintegrating tablets) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2022 Aug.28415 - Nora Goldschlager, Andrew E Epstein, Blair P Grubb, et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003;163:151-62.28419 - Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:301-19.28420 - Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002;1:121-8.28421 - Levaquin (levofloxacin) tablet package insert. Titusville, NJ: Janssen Pharmaceutical, Inc.; 2020 Jun.28423 - Avelox (moxifloxacin) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2020 May.28424 - Factive (gemifloxacin mesylate) package insert. Toronto, ON: Merus Labs International, Inc.; 2019 May.28432 - Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.28442 - Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2023 Nov.28457 - Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.28458 - Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-44.28592 - Zoladex (goserelin acetate 3.6 mg implant) package insert. Lake Forest, IL: TerSera Therapeutics LLC; 2023 March28611 - Prograf (tacrolimus) capsules, injection, and granules for oral suspension package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2023 Aug.28661 - Apokyn (apomorphine injection) package insert. Rockville, MD: MMD US Operations, LLC; 2022 Jun28674 - Diflucan oral tablet and suspension (fluconazole) package insert. New York, NY: Pfizer; 2024 Feb.28737 - Droperidol injection package insert. Shirley NY: American Regent, Inc. 2023 Mar.28752 - Thevenin J, Da Costa A, Roche F, et al. Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol 2003;26:1907-8.28754 - Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003;98:639-42.28755 - Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001;56:248-50.28756 - Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662-4.28785 - Zyprexa (olanzapine, all oral formulations and injectable solution) package insert. Indianapolis, IN: Eli Lilly and Company; 2020 Apr.28822 - Fareston (toremifene citrate) tablets package insert. Bedminster, NJ: Kyowa Kirin Inc.; 2017 May.28834 - Cuprimine (penicillamine) package insert. Lawrenceville, NJ: Atom Pharma; 2010 Mar.28855 - Zithromax (azithromycin 250 mg and 500 mg tablets and azithromycin oral suspension) package insert. New York, NY: Pfizer Inc.; 2021 Nov.28879 - Pentamidine isethionate injection package insert. East Brunswick, NJ: Avet Pharmaceuticals Inc.; 2021 Jan.28995 - Invirase (saquinavir) package insert. South San Francisco, CA: Genentech Inc.; 2020 Sept.28996 - Septocaine (articaine; epinephrine injection) package insert. Louisville, CO: Septodont, Inc.; 2018 Nov.29062 - Nesacaine (chloroprocaine hydrochloride) package insert. Lake Zurich, IL: Fresenius Kabi USA, LLC; 2018 Nov.29064 - Citanest Plain Dental (prilocaine) injection package insert. York, PA: AstraZeneca; 2018 Nov.29100 - Carbocaine (mepivacaine hydrochloride) package insert. Lake Forest, IL: Hospira, Inc.; 2023 Dec.29118 - Seroquel (quetiapine fumarate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022 Jan.29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.30106 - Imodium A-D Liquid and Caplets (loperamide HCL) consumer product labels. Fort Washington, PA: Johnson and Johnson Consumer Inc., McNeil Consumer Healthcare Division; 2019.30163 - Agrylin (anagrelide) capsules package insert. Lexington, MA: Takeda Pharmaceuticals USA, Inc.; 2021 Oct.30284 - McElnay JC, Mukhtar HA, D' Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg 1982;85:153-8.30285 - McElnay JC, Mukhtar HA, D' Arcy PF, et al. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg 1982;85:159-63.30369 - Vantas (histrelin implant) package insert. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc.; 2022 Feb.30515 - Vesicare (solifenacin) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2012 Jul.30738 - Ofloxacin tablets package insert. Sacramento, CA: Nivagen Pharmaceuticals, Inc.; 2019 Feb.31112 - Detrol (tolterodine tartrate) package insert. New York, NY: Pharmacia and Upjohn Co., division of Pfizer; 2016 Nov.31217 - Penicillin G procaine package insert. New York, NY: Pfizer Inc; 2023 Sep.31266 - Zofran (ondansetron) injection package insert. Research Triangle Park, NC: GlaxoSmithKline; 2021 Oct.31353 - Synera (lidocaine; tetracaine) package insert. Sounderton, PA: Galen US Inc.; 2020 Dec.31403 - Qualaquin (quinine sulfate) capsules package insert. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2019 Jun.31723 - Kytril injection (granisetron) package insert. Nutley, NJ: Roche Pharmaceuticals; 2011 Nov.31832 - Nexavar (sorafenib) package insert. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc.; 2020 July.31938 - Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2019 Oct.32127 - Prozac (fluoxetine) capsules package insert. Indianapolis, IN: Eli Lilly and Company; 2023 Aug.32387 - Sprycel (dasatinib) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014 April.32722 - Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100.32723 - Noxafil (posaconazole) package insert. Whitehouse Station, NJ: Merck & Co. Inc.: 2022 Jan.32732 - Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-51.32734 - Su KP, Lane HY, Chuang CL, et al. Olanzapine-induced QTc prolongation in a patient with wolff-parkinson-white syndrome. Schizophrenia Research 2004;66:191-2.32745 - Dineen S, Withrow K, Voronovitch L, et al. QTc prolongation and high-dose olanzapine. Psychosomatics 2003;44:174-5.32789 - Zolinza (vorinostat) capsules package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2018 Dec.33068 - Gajwani P, Pozuelo L, Tesar G, et al. QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics 2000;41:63-5.33072 - Beelen AP, Yeo KTJ, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.33074 - Furst BA, Champion KM, Pierre JM, et al. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 2002;51:264-5.33136 - Methadone hydrochloride tablets package insert. Webster Groves, MO: SpecGx LLC; 2024 Jan.33192 - Tykerb (lapatinib) tablet package insert. Research Triangle Park, NC: GlaxoSmithKline; 2022 March.33715 - Effexor XR (venlafaxine extended-release capsules) package insert. Morgatown, WV: Viatris Specialty LLC; 2023 Aug.34335 - Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001;40:343-73.34353 - Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet 1996;31:257-74.34389 - Xenazine (tetrabenazine) package insert. Deerfield, IL: Lundbeck, Inc.; 2017 Sep.35401 - Coartem (artemether; lumefantrine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019 Aug.36101 - Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2023 Oct.36146 - Fanapt (iloperidone) package insert. Washington, DC: Vanda Pharmaceuticals, Inc.; 2024 Apr.36250 - Sabril (vigabatrin) tablet/powder for oral solution package insert. Deerfield, IL: Lundbeck Inc.; 2021 Oct.36343 - Saphris (asenapine) sublingual tablet package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2017 Mar.36615 - Vibativ (telavancin) package insert. Nashville, TN: Cumberland Pharmaceuticals Inc.; 2020 July.36894 - Metronidazole injection package insert. Deerfield, IL: Baxter Healthcare Corporation; 2024 July.37098 - Votrient (pazopanib) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2011 Oct.37292 - Istodax (romidepsin) injection package insert. Summit, NJ: Celgene Corporation; 2021 July.38831 - Oleptro (trazodone hydrochloride) extended-release tablets package insert. Dublin, Ireland: Labopharm Europe Limited; 2014 Jul.40233 - Sporanox (itraconazole) oral solution package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Mar.40848 - Imovax Rabies (rabies vaccine) package insert. Swiftwater, PA: Sanofi-Pasteur Inc.; 2019 Oct.40849 - RabAvert (rabies vaccine) package insert. Hellerup, Denmark: Bavarian Nordic A/S; 2024 May.40936 - Invega Sustenna (paliperidone palmitate injectable suspension) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Sept.40942 - Remeron and Remeron SolTabs (mirtazapine tablets and ODT tablets) package insert. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2021 Nov.41124 - Staxyn (vardenafil orally disintegrating tablets) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2023 Apr.41235 - Butrans (buprenorphine transdermal system) package insert. Stamford, CT: Purdue Pharma L.P.; 2023 Dec.41806 - Plaquenil (hydroxychloroquine) package insert. Dublin, Ireland: Amdipharm Limited; 2023 Dec.41830 - Corvert (ibutilide) package insert. New York, NY: Pharmacia and Upjohn Company; 2023 Nov.41958 - Eloxatin (oxaliplatin) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2023 June.41984 - Primaquine phosphate package insert. Bridgewater, NJ: Sanofi-aventis; 2017 Jun.42039 - Quelicin (succinylcholine) injection package insert. Lake Forest, IL: Hospira, Inc.; 2022 Nov.42121 - Pradaxa (dabigatran) oral capsules package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2023 Nov.42280 - Nuedexta (dextromethorphan hydrobromide; quinidine sulfate capsule) package insert. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; 2019 Jun.42449 - Halaven (eribulin mesylate) injection package insert. Woodcliffe Lake, NJ: Eisai Inc.; 2022 Sept.42844 - FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Retrieved December 17, 2010. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.42845 - Abilify (aripiprazole) tablets, discmelt orally-disintegrating tablets, oral solution, and intramuscular injection package insert. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2022 Nov.43065 - Chlorpromazine package insert. Princeton, NJ: Sandoz Inc; 2019 Dec.43258 - Eryped (erythromycin ethylsuccinate) package insert. Atlanta, GA: Arbor Pharmaceuticals, INC.; 2018 Apr.43383 - Xylocaine (lidocaine injection), Xylocaine (lidocaine and epinephrine injection) package insert. Lake Zurich, IL: Fresenius Kabi; 2018 Nov.43411 - Cipro (ciprofloxacin tablet; suspension) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2024 Sept.43463 - Pimozide tablets package insert. Chestnut Ridge, NY: Par Pharmaceuticals; 2017 March.43800 - Lupron Depot (leuprolide acetate for depot suspension) package insert. North Chicago, IL: AbbVie Inc; 2024 March.43901 - Caprelsa (vandetanib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024 March.43974 - Zithromax (azithromycin injection) package insert. New York, NY: Pfizer Inc.; 2021 Nov.44058 - Prozac Weekly (fluoxetine hydrochloride delayed-release capsules) package insert. Indianapolis, IN: Lilly USA, LLC; 2017 Mar.44059 - Fluoxetine hydrochloride tablets for PMDD package insert (generic to Sarafem). Basking Ridge, NJ: TORRENT PHARMA INC; 2023 Aug.44376 - Edurant (rilpivirine) package insert. Titusville, NJ: Janssen Therapeutics; 2024 Mar.44406 - Fosrenol (lanthanum carbonate chewable tablets and oral powder) package insert. Lexington, MA: Takeda Pharmaceuticals, America, Inc.; 2024 Aug.45335 - Zelboraf (vemurafenib) tablet package insert. South San Francisco, CA: Genentech USA, Inc.; 2020 May.45411 - Trelstar (triptorelin pamoate for injectable suspension) package insert. Ewing, NJ: Verity Pharmaceuticals, Inc.; 2024 April.45458 - Xalkori (crizotinib) capsules and pellets package insert. New York, NY: Pfizer Labs; 2023 Sept.46869 - Firmagon (degarelix) package insert. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2020 Dec.47129 - Hydroxyzine hydrochloride injection package insert. Miami, FL: Atlantic Biologicals Corp; 2019 Sept.47221 - Propulsid (cisapride) package insert. Titusville, NJ; Janssen Pharmaceutica; 2006 Oct. NOTE: As of May 2000; Propulsid has only been available in the United States via an investigational limited access program to ensure proper patient screening and prescribing.47357 - Quinidine gluconate extended-release tablet package insert. Princeton, NJ: Eywa Pharma Inc.; 2021 Dec.47391 - Intron A (interferon alfa-2b, recombinant) package insert. Whitehouse Station, NJ: Merck & Co, Inc.; 2021 Nov.48697 - Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics; 2019 Nov.50507 - Luvox CR (fluvoxamine maleate extended-release capsules) package insert. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2017 Jan.51070 - Tambocor (flecainide) package insert. Scottsdale, AZ: Medicis, The Dermatology Company; 2011 Dec.51289 - Droperidol injection package insert. Shirley NY: American Regent, Inc. 2023 Mar.51740 - Maprotiline HCl tablet package insert. Morgantown WV: Mylan Pharmaceuticals Inc; 2014 Dec.52330 - Ropivacaine injection package insert. Berkeley Heights, NJ: Hikma Pharmaceuticals USA, Inc.; 2020 Nov.52331 - Marcaine (bupivacaine) injection package insert. Lake Forest, IL: Hospira, Inc.; 2020 Aug.52603 - Iclusig (ponatinib) tablet package insert. Cambridge, MA: Takeda Pharmaceuticals Company Limited; 2024 Mar.52746 - Sirturo (bedaquiline) tablets package insert. Horsham, PA: Janssen Products, LP; 2024 Jun.53394 - Abilify Maintena (aripiprazole) extended-release intramuscular injection package insert. Rockville, MD:Otsuka America Pharmaceutical, Inc.; 2020 June.55401 - Astagraf XL (tacrolimus extended-release capsules) package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2023 Aug.55578 - Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarization: a double-blind, midazolam-controlled study. Anaesthesia 2009;64:609-614.57094 - Zykadia (ceritinib) package insert. Indianapolis, IN: Novartis; 2021 Oct.57441 - Iribarren C, Round AD, Peng JA, et al. Validation of a population-based method to assess drug-induced alterations in QT interval: a self-controlled crossover study. Pharmacoepidemiol Drug Saf 2013;22;1222-32.57803 - Cerdelga (eliglustat) capsules. Waterford, Ireland: Genzyme Ireland, Ltd.;2018 Sept.58685 - Savaysa (edoxaban) package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2023 Oct.58766 - Tasigna (nilotinib) capsules package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024 Feb.58782 - Lenvima (lenvatinib) package insert. Woodcliff Lake, NJ:Eisai Inc; 2024 June.58821 - Farydak (panobinostat) capsules package insert. Las Vegas, NV: Secura Bio, Inc.; 2021 Sept.59321 - CredibleMeds. QT drug lists. Available on the World Wide Web at http://www.crediblemeds.org.59322 - Howes LG. Cardiovascular effects of drugs used to treat alzheimer's disease. Drug Saf. 2014;37:391–395.59809 - Mamiya K, Sadanaga T, Sekita A, et al. Lithium concentration correlates with QTc in patients with psychosis. J Electrocardiol 2005;38:148-51.59810 - van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15.59811 - Altinbas K, Guloksuz S, Caglar IM, et al. Electrocardiography changes in bipolar patients during long-term lithium monotherapy. Gen Hosp Psychiatry 2014;36:694-7.60196 - Aristada (aripiprazole lauroxil) extended-release intramuscular suspension package insert. Waltham, MA: Alkermes, Inc.; 2020 Feb.60270 - Belbuca (buprenorphine) buccal film package insert. BioDeliviery Sciences International, Inc.: Raleigh, NC; 2023 Dec.60281 - Cotellic (cobimetinib) tablets package insert. San Francisco, CA: Genentech USA, Inc; 2023 May.60297 - Tagrisso (osimertinib) tablet package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024 Sept.60372 - Mekinist (trametinib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024 July.60497 - Envarsus XR (tacrolimus) extended-release tablets. Cary, NC: Veloxis Pharmaceuticals, Inc.; 2024 Apr.60612 - Aczone (dapsone gel 7.5%) package insert. Exton, PA: Almirall, LLC; 2019 Sept.60686 - Diflucan (fluconazole) injection package insert. New York, NY: Pfizer; 2024 Feb.60748 - Nuplazid (pimavanserin) package insert. San Diego, CA: Acadia; 2023 Sept.60864 - US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Retrieved June 7, 2016. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery60871 - Vaxchora (Cholera Vaccine, live, oral) package insert. Redwood City, CA: Emergent Travel Health Inc.; 2024 Jan.60957 - Avloclor (chloroquine phosphate) tablets. Summary of product characteristics. European package labeling. Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB United Kingdom: Alliance Pharmaceuticals; 2016 Jun. Accessed: July 9 , 2016. Available at: http://www.medicines.org.uk/emc/medicine/227261195 - Levofloxacin injection solution package insert. E. Windsor, NJ: AuroMedics Pharma LLC.; 2019 Mar.61470 - Vistaril (hydroxyzine pamoate) capsules and oral suspension package insert. New York, NY: Pfizer Laboratories; 2023 May.61759 - Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27:813-16.61760 - Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5(S1):S11-15.61761 - Ali HM. Reduced ampicillin bioavailability following oral coadministration with chloroquine. J Antimicrob Chemother 1985;15:781-4.61816 - Kisqali (ribociclib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024 Sept.61845 - Austedo and Austedo XR (deutetrabenazine) tablets package insert. Parsippany, NJ: Teva Neuroscience, Inc.; 2024 May.61872 - Slovacek L, Ansorgova V, Macingova Z, et al. Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther. 2008;33(4):453-5.61906 - Rydapt (midostaurin) capsule package insert. East Hanover,NJ: Novartis Pharmaceuticals Corporation; 2023 May.62037 - Bevyxxa (betrixaban) capsules package insert. South San Francisco, Ca: Portola Pharmaceuticals, Inc.; 2020 Aug.62245 - Besponsa (inotuzumab ozogamicin) injection package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2024 Mar.62292 - Mylotarg (gemtuzumab ozogamicin) injection package insert. Philadelphia, PA: Pfizer Inc.; 2020 Feb.62723 - Macrilen (macimorelin) package insert. Frankfurt am Main, Germany: Aeterna Zentaris GmbH; 2018 Jan.63161 - Lucemyra (lofexidine) tablets package insert. Louisville, KY: US WorldMeds, LLC; 2018 May.63317 - Braftovi (encorafenib) capsules package insert. Boulder, CO: Array BioPharma Inc.; 2024 Sep.63589 - Soltamox (tamoxifen) oral solution package insert. Raleigh, NC: Midatech Pharma US Inc.; 2019 April.63609 - Desyrel (trazodone) package insert. Locust Valley, NY: Pragma Pharmaceuticals, LLC.; 2017 June.63729 - Levofloxacin premix injection package insert. E. Windsor, NJ: Eugia US LLC; 2024 Jun.63777 - Daurismo (glasdegib) tablets package insert. New York, NY: Pfizer Labs; 2023 Mar.63787 - Xospata (gilteritinib) tablets package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2022 Jan.63821 - Tolsura (itraconazole) capsules package insert. Greenville, NC: Mayne Pharma; 2018 Dec.63936 - Lamprene (clofazimine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019 Jan.63962 - Egaten (triclabendazole) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2022 Feb.64031 - Mayzent (siponimod) tablets package insert. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2024 Jun.64391 - Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441-e449.64392 - Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.64394 - O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.64396 - Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics 2018;59:105-122.64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.64567 - Rozlytrek (entrectinib) package insert. South San Francisco, CA: Genentech Inc.; 2024 Jan.64576 - Xenleta (lefamulin) package insert. Dublin, Ireland: Nabriva Therapeutics US, Inc.; 2021 Mar.64608 - Pentostam (sodium stibogluconate injection) package leaflet: Information for the healthcare professional. Middlesex, United Kingdom: GlaxoSmithKline UK; 2014 Feb.65068 - Barhemsys (amisulpride) package insert. Indianapolis, IN: Acacia Pharma Inc; 2021 May.65098 - Isturisa (osilodrostat) tablet package insert. Lebanon, NJ: Recordati Rare Disease, Inc.; 2020 Mar.65157 - CredibleMeds. COVID-19 experimental therapies and TdP risk. Available on the World Wide Web at http://https://crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk. Accessed March 23, 2020.65169 - Ozanimod (Zeposia) capsules package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2024 Aug.65170 - Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19 [published online ahead of print, March 25, 2020]. Mayo Clin Proc 2020;95.65210 - University of Liverpool. COVID-19 Drug Interactions. Retrived April 6, 2020. Available on the World Wide Web at https://www.covid19-druginteractions.org/.65237 - Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 1996;7:568-578.65239 - Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003;31:748-754.65365 - Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization (EUA) of Veklury (remdesivir) for treatment of coronavirus disease 2019 (COVID-19) in pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age weighing at least 3.5 kg, with positive results of direct SARS-CoV-2 viral testing. Retrieved January 22, 2022. Available on the World Wide Web at https://www.fda.gov/media/137566/download65387 - Retevmo (selpercatinib) capsules and tablets package insert. Indianapolis, IN: Eli Lilly and Company; 2024 Sept.65666 - Rukobia (fostemsavir) package insert. Durham, NC: ViiV Healthcare; 2024 Feb.66063 - Veklury (remdesivir) injection package insert. Foster City, CA: Gilead Sciences, Inc; 2024 Jun.66183 - Orgovyx (relugolix) tablets package insert. Brisbane, CA: Myovant Sciences, Inc.; 2023 Mar.66336 - Lupkynis (voclosporin) capsules package insert. Rockville, MD: Aurinia Pharma U.S., Inc.; 2024 Apr.66527 - Ponvory (ponesimod) tablet package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Jun.66812 - Fexinidazole package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2024 Sept.66990 - Exkivity (mobocertinib) capsules package insert. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2023 Sept.67231 - Recorlev (levoketoconazole) package insert. Chicago, IL: Xeris Pharmaceuticals, Inc.; 2021 Dec.67427 - Vonjo (pacritinib) capsules package insert. Seattle, WA: CTI BioPharma Corp; 2023 Aug.67509 - Igalmi (dexmedetomidine) sublingual film package insert. New Haven, CT: BioXcel Therapeutics, Inc.; 2022 Apr.68325 - Krazati (adagrasib) tablets package insert. San Diego, CA: Mirati Therapeutics, Inc.; 2024 June.69114 - Velsipity (etrasimod) package insert. New York, NY: Pfizer, Inc.; 2024 Jun.69220 - Vanflyta (quizartinib) tablets package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2024 July.70477 - Duvyzat (givinostat) oral suspension package insert. Concord, MA: ITF Therapeutics, LLC; 2024 March70577 - Xolremdi (mavorixafor) capsules package insert. Boston, MA: X4 Pharmaceuticals, Inc.; 2024 Apr.

    Monitoring Parameters

    • blood glucose
    • CBC
    • ECG
    • glucose-6-phosphate dehydrogenase (G6PD) activity
    • ophthalmologic exam

    US Drug Names

    • Aralen
    Small Elsevier Logo

    Cookies são usados neste site. Para recusar ou saber mais, visite nosso página de cookies.


    Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

    Small Elsevier Logo
    RELX Group